| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
MiMedx Group, Inc$4.11
-0.03 (-0.72%)
D 35Pipeline Score MedTech · Commercial
Market Cap
539.18 M
EPS
0.21
P/E Ratio
17.72 $
Value Trade
4.64 M
SEC Financials
Q1 2026Dilution Risk
Revenue
58.99 M
R&D Expenses
4.14 M
Operating CF
1.88 M
Total Assets
308.68 M
Total Liabilities
65.74 M
Equity
242.94 M
D/E Ratio
12,345
2.55 %
Week
12.77 %
1 Month
-30.25 %
3 Month
-44.39 %
6 Month
-61.69 %
5 Year
1,070.99 %
All Time
Cash Data
Cash Position
159.77 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 29, 2026
Overview
Volume
670.18 K
52 Week Range
3.03 - 7.99
% held by Insiders
20.98 %
% held by Institutions
57.04 %
Enterprise Value
397.00 M
Total Shares
148.05 M
Short %
6.44 %
Float Shares
116.96 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D35
Pipeline Score $196M
Pipeline ValueValuation Signal
1
Drugs Scored0.4x
rNPV / MCap Top 47%
Micro Cap (rank 484 of 912)
Percentile RankMiMedx Group, Inc faces pipeline headwinds (35/100), with $491M risk-adjusted pipeline value, led by Micronized DHACM in Tendonitis;Achilles (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Micronized DHACM Monoclonal antibody | Tendonitis;Achilles | Phase 3 | NCT03414255 | 68% | $491M | COMPLETED | 146 | - | - | Mar 30, 2021 | - | May 19, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
EPIEFFECT | diabetic foot ulcers | — | 2025-11-13 | The interim results of the CAMPAIGN trial indicate that EPIEFFECT demonstrated a superior clinical benefit over standard of care for nonhealing diabetic foot ulcers, with a posterior probability of 98.5% based on 71 enrolled patients. Read More | MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial Read More | |
EPIEFFECT | diabetic foot ulcers | — | 2025-11-13 | The interim results of the CAMPAIGN trial indicate that EPIEFFECT demonstrated a superior clinical benefit over standard of care for nonhealing diabetic foot ulcers, with a posterior probability of 98.5% based on 71 enrolled patients. Read More | MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial Read More | |
EPIEFFECT | diabetic foot ulcers | — | 2025-11-13 | The interim results of the CAMPAIGN trial indicate that EPIEFFECT demonstrated a superior clinical benefit over standard of care for nonhealing diabetic foot ulcers, with a posterior probability of 98.5% based on 71 enrolled patients. Read More | MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MDXG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MDXG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MDXGMIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
MiMedx Group, Inc. announced its participation in the Craig-Hallum 23rd Annual Institutional Investor Conference scheduled for May 28, 2026, in Minneapolis, MN. Senior management will be available for meetings with interested investors. The company is recognized for its innovative solutions in wound care and healing.
Read more →MDXGMIMEDX Announces Launch of G4Derm® Plus
MiMedx Group, Inc. has launched G4Derm Plus, a flowable biomimetic matrix designed for advanced wound management. The product, which utilizes self-assembling peptide technology, is now available through major group purchasing organizations like Premier and Vizient. Initial sales have been reported, indicating strong demand. Experts believe it will enhance treatment options for complex wounds.
Read more →MDXG▼ -9.3%on this news
MIMEDX Announces First Quarter 2026 Operating & Financial Results
MiMedx Group, Inc. reported its first quarter 2026 results, revealing net sales of $59 million, a significant drop from $88 million in the same quarter last year. The decline is primarily attributed to the impact of new Medicare reimbursement policies on their wound care products, which faced a 60% decrease in sales. Despite challenges, the surgical division showed a 13% increase in sales, and management is optimistic about recovering sales volumes in wound care settings. They have also revised their financial expectations for the full year downward and anticipate cost benefits from restructuring efforts.
Read more →MDXGMIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29
MiMedx Group, Inc. will announce its first quarter 2026 operating and financial results on April 29, 2026. The results will be shared in a conference call starting at 4:30 p.m. Eastern Time. Investors can access the call via a dedicated phone line or webcast, with a replay available for 30 days afterward.
Read more →MDXG▼ -11.6%on this news
MIMEDX Announces Restructuring and Cost Reduction Initiative
MiMedx Group, Inc. announced a restructuring initiative to reduce operating expenses by approximately $40 million. The elimination of the COO position is part of this effort, as the company aims to streamline operations and prioritize growth. The Wound Care business is recovering slowly from recent Medicare reimbursement reductions, prompting these changes.
Read more →MDXG▼ -11.6%on this newsshared move
forth in the forward-looking statements. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement. About MIMEDX MIMEDX i
MIMEDX has announced a major restructuring aimed at improving profitability by reducing annual operating expenses by approximately $40 million. This organizational change comes as the company faces slow recovery in its Wound Care business following a reduction in Medicare reimbursements. The position of Chief Operating Officer has been eliminated as part of these changes, indicating a significant shift in the company's operational structure. Leadership change and adjustments are expected to be discussed in an upcoming quarterly conference call.
Read more →MDXGMIMEDX to Sponsor Leading Advanced Wound Care Conferences
MiMedx Group, Inc. will participate in two prominent wound care conferences, SAWC Spring 2026 and DLS 2026. The company plans to present its advanced wound care technologies and clinical evidence through various sessions. MIMEDX aims to support clinicians in managing complex wounds and improve patient outcomes with innovative solutions.
Read more →MDXGMIMEDX Announces Launch of CHORIOFIX™
MiMedx Group, Inc. has launched CHORIOFIX, an advanced wound care product featuring two chorion layers and an intact intermediate layer. This product is designed to enhance handling during application and is particularly suited for complex wound types. CHORIOFIX will also be evaluated in the CAMPAIGN trial against standard care for diabetic foot ulcers.
Read more →MDXGMIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields
MiMedx Group, Inc. has launched AMNIOFIX Thyroid Shields, a new product designed for use in endocrine surgery. These allografts provide a protective barrier for the recurrent laryngeal nerve and parathyroid glands post-thyroidectomy, significantly reducing the risk of nerve damage. The product is shelf-stable for five years and aims to improve surgical outcomes.
Read more →MDXG▼ -6.4%on this news
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
MiMedx Group, Inc. reported record financial results for Q4 and full year 2025, with net sales increasing by 27% year-over-year. The company achieved a GAAP net income of $15 million and an Adjusted EBITDA margin of 25%. Looking ahead, MiMedx anticipates 2026 net sales between $340-360 million, despite potential short-term impacts from Medicare reimbursement changes.
Read more →MDXGMIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25
MiMedx Group, Inc. will announce its operating and financial results for Q4 and the full year 2025 on February 25, 2026. The results will be shared during a conference call hosted by the senior management team at 4:30 p.m. ET. Investors can access the call via a dedicated phone line or webcast.
Read more →MDXGMIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products
MiMedx Group, Inc. has entered an exclusive distribution agreement with Summit Products Group to distribute three innovative surgical and wound care products: Hydrelix, NovaForm, and G4Derm Plus. This partnership aims to enhance MiMedx's existing product portfolio and strengthen its position in the Surgical & Wound markets. The agreement reflects MiMedx's commitment to innovation and quality in healthcare solutions.
Read more →MDXGMIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
MiMedx Group, Inc. celebrates the 15th anniversary of its placental allografts, EPIFIX and AMNIOFIX. These products have significantly impacted wound care and surgical recovery, being recognized for their extensive clinical studies and peer-reviewed data. The company highlights its commitment to innovation and improving patient outcomes in various surgical fields.
Read more →MDXGMIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit -Wound Gel
MiMedx Group, Inc. has announced an exclusive distribution agreement with Regen Lab USA LLC for their RegenKit-Wound Gel in the U.S. This product is an autologous platelet-rich plasma and thrombin serum gel designed for chronic wound treatment, supported by various studies. The agreement adds an innovative option to MIMEDX's Advanced Wound Care portfolio. Additionally, a recent regulatory clarity on Local Coverage Determination will bolster the company's market position starting in January 2026.
Read more →MDXGMIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro
MiMedx Group, Inc. announced a new publication in the Journal of Inflammation detailing the immunomodulatory effects of its Purion processed human amniotic membrane allografts. The study found that both DHACM and LHACM products effectively regulate inflammatory responses, which could enhance wound healing. This research adds to MiMedx's extensive body of evidence supporting its innovative products.
Read more →MDXGMIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial
MiMedx Group, Inc. announced positive interim results from its CAMPAIGN trial evaluating EPIEFFECT for diabetic foot ulcers. The trial shows a 98.5% probability that EPIEFFECT outperforms standard of care. Enrollment is ongoing, and the results may influence Medicare coverage decisions set for January 2026.
Read more →MDXGMIMEDX to Participate in Upcoming Investor Conferences
MiMedx Group, Inc. announced its participation in two upcoming investor conferences in New York. Senior management will engage in one-on-one sessions at the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025, and the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025. This engagement reflects the company's focus on investor relations and commitment to its innovative healing solutions.
Read more →MDXGMIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule
MiMedx Group, Inc. commented on the CY 2026 Medicare Physician Fee Schedule final rule, expressing optimism about the reforms aimed at reducing fraud and improving the reimbursement system for skin substitutes. CEO Joseph H. Capper highlighted the company's competitive advantages and readiness to adapt to the new environment, although he noted some missed opportunities for their recommendations. The company prioritizes ensuring patient access to their technology during this transition.
Read more →MDXGMIMEDX Announces Record Revenue for Third Quarter 2025
MiMedx Group, Inc. reported record net sales of $114 million for the third quarter of 2025, marking a 35% increase compared to the previous year. The company achieved its highest quarterly revenue and adjusted EBITDA, driven by strong growth in its Wound and Surgical product lines. Management raised expectations for 2025 net sales growth and adjusted EBITDA margins, indicating a positive outlook despite pending reimbursement rules from CMS.
Read more →MDXGMIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29
MiMedx Group, Inc. will announce its third quarter 2025 operating and financial results on October 29, 2025. The announcement will be followed by a conference call at 4:30 p.m. Eastern Time, where senior management will review the results. Investors can access the call via a webcast or by phone.
Read more →MDXGMIMEDX Announces Launch of EPIXPRESS®
MiMedx Group, Inc. has launched EPIXPRESS®, a new addition to its AWC solutions. This lyophilized human placental allograft features fenestrations for improved fluid movement and is designed for treating various hard-to-heal wounds, including diabetic foot ulcers and venous leg ulcers. EPIXPRESS builds on the success of EPIEFFECT, enhancing MIMEDX's commitment to innovation in wound care.
Read more →MDXGMIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall
MiMedx Group, Inc. will participate in the Symposium on Advanced Wound Care (SAWC) Fall from September 3-6 in Las Vegas, NV. The company will exhibit its advanced wound care products and host a sponsored lunch symposium discussing innovative treatment approaches. Additionally, six of its clinical and scientific posters have been accepted for presentation at the event.
Read more →MDXG▲ +10.3%on this news
MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results
MIMEDX reported record second quarter 2025 results with net sales of $99 million, reflecting a 13% year-over-year growth. The company achieved an adjusted EBITDA of $24 million, representing 25% of net sales. Despite a decrease in net income compared to the previous year, management remains optimistic, raising their growth expectations for the year.
Read more →MDXGMIMEDX Announces Strategic Collaboration with Vaporox, Inc.
MiMedx Group, Inc. has announced a strategic collaboration with Vaporox, Inc. to co-promote their wound care products. MiMedx has invested in Vaporox and secured exclusivity rights for potential acquisition discussions. Vaporox's Vaporous Hyperoxia Therapy device, which has FDA clearance, is expected to complement MiMedx's offerings in treating chronic wounds.
Read more →MDXG▲ +6%on this news
MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30
MiMedx Group, Inc. announced that it will report its operating and financial results for the second quarter of 2025 on July 30, after market close. The senior management team will conduct a conference call to discuss the results, scheduled for 4:30 p.m. ET the same day. The event indicates the company's continuous engagement in financial transparency and performance update for investors.
Read more →MDXG▼ -6.9%on this newsshared move
MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026
MiMedx Group, Inc. (MDXG) has expressed support for the proposed Medicare reimbursement rule changes for CY 2026, which includes a fixed price for skin substitutes. The company highlighted the previous inefficiencies in reimbursement methodology that led to excessive spending. CEO Joseph H. Capper emphasized the need for reform to restore rational market behavior and combat fraud. MIMEDX looks forward to participating in the comment period with CMS and is optimistic about navigating the evolving regulatory landscape.
Read more →MDXGMIMEDX to Present at the BofA Securities 2025 Healthcare Conference
MiMedx Group, Inc. (Nasdaq: MDXG) has announced that its senior management will present at the BofA Securities 2025 Healthcare Conference in Las Vegas on May 13, 2025. The conference provides an opportunity for investors to meet with the management team to discuss the company’s portfolio and strategies. MiMedx is recognized for its dedication to healing solutions through innovation, especially in wound care and surgical applications.
Read more →MDXGMIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)
MiMedx Group, Inc. has announced the publication of health economics data related to the use of its product EPIFIX in Mohs micrographic surgery. The study, published in the Journal of Drugs in Dermatology, shows that DHACM significantly reduces complications compared to traditional methods. Patients treated with placental allografts experienced fewer postoperative issues and faster recovery times. The findings are expected to influence healthcare decision-making related to cost-effectiveness in high-risk surgical procedures.
Read more →MDXGMIMEDX Announces First Quarter 2025 Operating and Financial Results
MiMedx Group, Inc. reported its first-quarter 2025 operating results, showing net sales of $88 million, a 4% increase year-over-year. The company experienced significant growth in its Surgical products, which contributed to an Adjusted EBITDA margin of 20%. However, net income decreased from $9 million to $7 million compared to the prior year, partly due to increasing selling, general and administrative expenses. Management reaffirmed its expectations for continued net sales growth in 2025, despite challenges from regulatory actions and pricing for products.
Read more →MDXGMIMEDX to Host First Quarter 2025 Operating and Financial Results Conference Call on April 30
MiMedx Group, Inc. (MDXG) has announced its plans to report financial results for the first quarter of 2025 on April 30, after market close. A conference call and webcast will be held the same day at 4:30 p.m. Eastern Time for a discussion of these results. This event aligns with MIMEDX's commitment to transparency and engagement with its investors.
Read more →MDXGMIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences
MiMedx Group, Inc. (MDXG) is set to participate in several key industry conferences this spring to present its latest clinical and scientific evidence for its Advanced Wound Care and Surgical Solutions. CEO Joseph H. Capper emphasized the company's ongoing commitment to innovation and the growing body of evidence supporting their products. Notable conferences include the Diabetic Limb Salvage Conference, Symposium on Advanced Wound Care Spring 2025, and Digestive Disease Week 2025, where MIMEDX aims to enhance awareness and adoption of its solutions in various medical fields.
Read more →MDXGMIMEDX to Present at TD Cowen 45th Annual Health Care Conference
MiMedx Group, Inc. will be presenting at the TD Cowen 45th Annual Health Care Conference from March 3-5, 2025, in Boston, MA. The presentation is scheduled for March 4 at 11:10 AM ET, and a live webcast will be available for investors. MiMedx has established itself as a leader in wound care, emphasizing their commitment to innovation and quality of life enhancement for patients. Interested parties can also meet with senior management through TD Cowen representatives.
Read more →MDXGearningscallpresent Financial Results Conference Call
MIMEDX Group reported strong financial results for the fourth quarter and full year of 2024, with net sales increasing by 7% to $93 million. The company highlighted significant growth in its adjusted EBITDA and expanding market presence, particularly in Japan. While financial results were promising, MIMEDX cautioned investors regarding potential risks, including uncertainties around future sales and regulatory approval processes. The firm remains focused on innovation and strategic growth plans for 2025, despite potential challenges in the reimbursement landscape.
Read more →MDXGMIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results
MiMedx Group, Inc. announced strong operating and financial results for the fourth quarter and full year 2024, reporting a 7% increase in net sales year-over-year for Q4 and a 9% increase for the full year. The company achieved an Adjusted EBITDA margin of 21% and noted a significant cash position of $104 million. However, MiMedx faces ongoing challenges due to Medicare reimbursement system issues and rising selling expenses. Management remains optimistic about future growth potential and plans to expand its Wound and Surgical businesses.
Read more →MDXGMIMEDX to Host Fourth Quarter and Full Year 2024 Operating and Financial Results Conference Call on February 26
MiMedx Group, Inc. (Nasdaq: MDXG) will release its operating and financial results for Q4 and the full year 2024 on February 26, 2025, after market close. A conference call will be held at 4:30 p.m. ET on the same day to discuss these results. This announcement underscores MIMEDX's ongoing activities and commitment to its stakeholders.
Read more →MDXGInvestor Presentation January 2025 Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions inv
The investor presentation from MIMEDX Group emphasizes the company's expansive vision and growth potential in the healing solutions market. It outlines the promising prospects for their placental-derived product offerings and various planned expansions, particularly outside the U.S. However, the presentation includes cautionary notes about the uncertainties surrounding forward-looking statements, regulatory challenges, competition, and the reimbursement landscape, which could impact future performance.
Read more →MDXGMIMEDX Files Patent Infringement Lawsuit Against Surgenex
MiMedx Group, Inc. has filed a patent infringement lawsuit against Surgenex, LLC, claiming that Surgenex's products violate its patents. This legal action follows a previous lawsuit related to alleged unfair competitive practices. CEO Joseph H. Capper highlighted the company's extensive patent portfolio and commitment to protecting its intellectual property. MiMedx continues to focus on innovation in the wound care and healing solutions market.
Read more →MDXGDisclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue relian
MIMEDX presented a cautionary overview concerning forward-looking statements on sales growth, product demand, and regulatory approvals that may impact their financial outlook. The company highlighted both the growth potential in placental-derived products for wound healing and the strategic priorities aimed at expanding their market presence. However, they stressed the inherent risks, including the uncertain market conditions and lengthy regulatory processes. MIMEDX's established research base showcases the effectiveness of its products, yet future performance remains uncertain.
Read more →MDXG▲ +23.6%on this newsshared move
MIMEDX’s Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs
MiMedx Group, Inc. announced an update regarding the implementation of new Local Coverage Determinations (LCDs) that will no longer cover over 200 unproven skin substitutes, starting February 12, 2025. This change stems from the company's advocacy efforts with CMS and MACs, which highlighted the need to address rising Medicare expenses associated with wound care. The revised LCDs include increased treatment applications and duration while emphasizing the necessity for peer-reviewed clinical evidence for reimbursement. MIMEDX expects to benefit from these changes, as their products EPIFIX® and EPICORD® are included in the list of covered items, promoting better patient access to proven solutions.
Read more →MDXGMIMEDX Announces Third Quarter 2024 Operating and Financial Results Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, Re
MIMEDX announced its financial results for Q3 2024, reporting $84 million in net sales, a 3% increase compared to the previous year. The company emphasized the strength of its product offerings and a solid EBITDA margin of 22%. Looking ahead, MIMEDX has raised its growth expectations for 2024 to high single digits. Challenges included turnover in the sales team and declines in specific product sales, but management remains optimistic about future growth.
Read more →MDXGMIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30
MiMedx Group, Inc. (MDXG) will report its operating and financial results for the third quarter of 2024 on October 30, 2024, after market close. The company's management team will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will provide insights into the company's performance and ongoing commitment to innovation in the healthcare sector, particularly in wound care.
Read more →MDXGMIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
MiMedx Group, Inc. (MDXG) has emphasized a New York Times feature on the advantages of placental allografts for treating hard-to-heal wounds. The article discusses the opportunity for mothers to donate placental tissue after C-sections, which MIMEDX utilizes in its products. CEO Joseph H. Capper noted his satisfaction with the increased visibility of this treatment area, despite the company not being specifically named in the article. Two patients featured in the article have successfully recovered with the help of MIMEDX products, showcasing their effectiveness.
Read more →MDXGMIMEDX Showcases Leading Allograft Portfolio and Its Latest Scientific and Clinical Evidence at SAWC Fall
MiMedx Group, Inc. (MDXG) announced its participation in the Symposium on Advanced Wound Care (SAWC) Fall meeting, taking place from October 2-5 in Las Vegas, NV. The company will sponsor a lunch symposium and a hands-on skills lab, highlighting its latest research and innovations in wound healing, specifically regarding placental tissue. Seven of its clinical and scientific posters have been accepted for display, further solidifying its commitment to leading scientific advancements in the wound care field. The event aims to connect healthcare professionals with the latest clinical evidence and treatment methodologies.
Read more →MDXGMIMEDX Announces Launch of HELIOGEN™ Fibrillar Collagen Matrix
MiMedx Group, Inc. announced the commercial launch of HELIOGEN™ Fibrillar Collagen Matrix, a new bovine-derived collagen product aimed at treating complex wounds, particularly in surgical settings. HELIOGEN is a 510(k) cleared product that allows for effective wound management by facilitating cell adhesion and migration. The launch reflects MIMEDX's strategy to expand its surgical portfolio following recent successful product introductions. The company is optimistic about the product's potential to improve patient outcomes, supported by initial case studies.
Read more →MDXGMIMEDX Announces Second Quarter 2024 Operating and Financial Results Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12
MiMedx Group, Inc. reported its second quarter 2024 financial results, highlighting a 7% year-over-year increase in net sales, totaling $87 million. The company achieved an adjusted EBITDA margin of 23%, despite facing commercial challenges from competitive behavior in the marketplace. CEO Joseph H. Capper noted employee and customer attrition due to these competitive pressures but expressed optimism about future prospects, including the release of their HELIOGEN product and ongoing discussions with regulatory bodies. MiMedx anticipates continued sales growth in the mid-to-high single-digits for the year, although this is tempered by uncertainties regarding Medicare reimbursement policies.
Read more →MDXGMIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
MiMedx Group, Inc. has published a peer-reviewed study in Nature - Scientific Reports highlighting the role of placental-based allografts in modulating fibrosis during surgical procedures. This study evaluates the effects of dehydrated and lyophilized human amnion chorion membranes on collagen production and proposes their potential to reduce pathological scarring. By contributing to the scientific literature, MIMEDX aims to support the efficacy of its products and explore further applications for enhancing patient care. This marks a significant milestone for the company as it reinforces its commitment to innovation in wound care and surgical solutions.
Read more →MDXGMIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
MiMedx Group, Inc. (Nasdaq: MDXG) announced that it will release its operating and financial results for the second quarter of 2024 on July 31 after market closure. The senior management team will conduct a conference call and webcast at 4:30 p.m. ET on the same day to discuss these results. This initiative reflects the company's ongoing commitment to transparency and innovation in the healthcare sector, particularly in wound care.
Read more →MDXGMIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
MiMedx Group, Inc. has appointed Kim Moller as Chief Commercial Officer, a promotion from her previous role as Senior Vice President of Sales. CEO Joseph H. Capper expressed confidence in Moller's leadership, highlighting her contributions to transforming MIMEDX's commercial organization over the past four years. In her new role, Moller will oversee marketing and international commercial operations, aiming to enhance the company's position as a global provider of medical solutions. Moller brings nearly 30 years of experience in healthcare sales leadership, previously working for notable companies like 3M.
Read more →MDXGMIMEDX Announces First Quarter 2024 Operating and Financial Results Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19
MIMEDX Group, Inc. reported its first-quarter 2024 operating and financial results, showcasing an 18% increase in net sales compared to the same quarter last year, amounting to $85 million. The company achieved a net income of $9 million, reversing a loss from the previous year. An adjusted EBITDA margin of 22% was noted, reflecting disciplined expense management. Additionally, MIMEDX plans to launch a strategic xenograft product later this year, aimed at enhancing its portfolio in the surgical market.
Read more →MDXGMIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30
MiMedx Group, Inc. will announce its operating and financial results for Q1 2024 on April 30, following market closure. A conference call to discuss these results will take place at 4:30 p.m. ET on the same day. The event will be accessible to both U.S. and international investors, with a replay available for 30 days post-event. MIMEDX continues to focus on innovation in wound care and aims to enhance quality of life through its products.
Read more →MDXGMIMEDX Provides Update on AXIOFILL Request for Designation (“RFD”) from FDA
MIMEDX has received a determination letter from the FDA stating that its product AXIOFILL does not qualify as a Human Cell, Tissue, or Cellular-based Product. The company has filed a lawsuit to challenge FDA's classification, asserting that the decision is inconsistent with similar products. Despite this setback, MIMEDX plans to continue marketing AXIOFILL while also introducing a new product later this year. The company maintains its financial guidance for 2024, projecting low double-digit sales growth.
Read more →MDXGMIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing
MiMedx Group, Inc. has announced an agreement with TELA Bio, Inc. to obtain exclusive rights to a manufacturing and supply agreement with Regenity Biosciences, adding xenograft products to its advanced wound care portfolio. The collaboration aims to enhance product offerings for the management of various wounds, integrating a new collagen matrix that supports healing. CEO Joseph H. Capper expressed optimism about the partnership and its role in achieving the company's growth objectives. The agreement involves an initial payment of $5 million and performance-based future payments linked to sales.
Read more →MDXGMIMEDX Introduces E-Commerce and Account Management Platform
MiMedx Group, Inc. has launched MIMEDX Connect, an e-commerce and account management platform aimed at enhancing customer experience. This online portal facilitates ordering, payment, and insurance verification directly through the company's website. With over 300 locations already using the platform, early feedback has been positive, highlighting time savings and simplified workflows. The initiative aligns with MIMEDX's commitment to support clinicians and enhance healthcare management.
Read more →MDXGMIMEDX Announces Appointment of Two New Independent Directors
MiMedx Group, Inc. has announced the appointment of Tiffany Olson and Dorothy Puhy as new independent directors on its Board, effective March 1, 2024. Both appointees have extensive experience in the healthcare industry and are expected to provide valuable insights to the Board. The company has also expanded its Board size to eleven directors to facilitate leadership growth and strategic direction. Executives at MiMedx express optimism about how these appointments will bolster the company's vision and impact in the wound care and surgical therapeutics sectors.
Read more →MDXGDocument MIMEDX Announces Appointment of Two New Independent Directors MARIETTA, Ga.
MiMedx Group, Inc. has appointed two new independent directors, Tiffany Olson and Dorothy Puhy, to its Board of Directors as of March 1, 2024. Both individuals bring substantial experience from their leadership roles in the healthcare sector and are expected to contribute positively to the company's strategic vision. The board has also expanded its size to eleven members in conjunction with these appointments, which signals a commitment to enhancing governance and shareholder value. Leaders at MiMedx express confidence that the new directors will help guide the company towards innovation in wound care and surgical therapeutics.
Read more →MDXGMIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive o
MiMedx Group, Inc. (Nasdaq: MDXG) announced strong operating and financial results for the fourth quarter and full year of 2023, highlighting a 17% increase in net sales for Q4 and a 20% increase for the entire year. The company achieved a net income of $53 million in the fourth quarter, reflecting a $40 million one-time non-cash tax benefit. Looking ahead, management expects to maintain low double-digit growth in 2024, bolstered by strong sales in their Wound & Surgical markets. The company is also gearing up for continued improvements in cash flow and overall financial performance.
Read more →MDXGMIMEDX to Present at TD Cowen 44th Annual Health Care Conference
MiMedx Group, Inc. (MDXG) announced its participation in the TD Cowen 44th Annual Health Care Conference, scheduled for March 4-6, 2024, in Boston, MA. Senior management will present at the conference on March 4 at 2:10 PM ET. The webcast of the presentation will be accessible through the company's website, with a replay available afterward. MiMedx continues to emphasize its commitment to innovation in the healing solutions space, particularly in wound care.
Read more →MDXGMIMEDX to Host Fourth Quarter and Full Year 2023 Operating and Financial Results Conference Call on February 28
MiMedx Group, Inc. (MDXG) will announce its fourth quarter and full-year financial results on February 28, 2024. The company plans to host a conference call and webcast to discuss these results, starting at 4:30 p.m. Eastern Time. MiMedx is recognized for its commitment to healing solutions and aims to lead in wound care and related healthcare sectors.
Read more →MDXGMIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution
MIMEDX has enhanced its capital structure by refinancing existing debt and securing new credit facilities totaling $95 million, which will improve its financial position and support future growth. The financing deal includes a $75 million revolving credit facility and a $20 million term loan, aimed at reducing interest expenses and providing additional borrowing capacity. The company plans to use these funds for both organic growth initiatives and potential acquisitions, reflecting its strong cash generation and financial performance in the previous year.
Read more →MDXGMiMedx Group Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
MiMedx Group, Inc. is being investigated by Block & Leviton for possible violations of securities laws after the company disclosed a warning letter from the FDA concerning its Axiofill product. The FDA indicated that Axiofill is improperly classified under regulations, which has led to concerns over its marketability and compliance. Following this news, MiMedx's stock experienced a significant drop of more than 10%. Investors who have incurred losses are encouraged to contact Block & Leviton for potential recovery actions.
Read more →MDXGMIMEDX ALERT: Bragar Eagel & Squire, P.C. is Investigating MiMedx Group, Inc. on Behalf of MiMedx Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating MiMedx Group, Inc. for potential claims regarding violations of federal securities laws. The investigation follows an FDA Warning Letter informing MiMedx that its product AXIOFILL is considered a Section 351 product, implying it requires more regulatory scrutiny. As a result of this negative news, MiMedx's stock experienced a substantial decline. Investors affected by the situation are encouraged to contact the law firm for more information.
Read more →MDXGMIMEDX Provides AXIOFILL Update & Reiterates 2023 Full Year Net Sales and Fourth Quarter Adjusted EBITDA Margin Outlook
MIMEDX announced an update regarding AXIOFILL, following an FDA warning letter that reclassified the product as a Section 351 item. The company disagrees with this position and remains engaged with the FDA through the Request for Designation process. Despite this regulatory setback, MIMEDX reaffirmed its outlook for 2023, projecting strong net sales growth and an EBITDA margin exceeding 20% in the fourth quarter. The CEO emphasized AXIOFILL's safety and the company's commitment to resolving the matter.
Read more →MDXGMIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock MARIETTA, Ga.
MIMEDX Group, Inc. has announced the automatic conversion of 95,000 shares of Series B Convertible Preferred Stock into approximately 30 million shares of Common Stock, effective December 22, 2023. This conversion was prompted by a rise in share price and comes three years after the initial financing transaction. The move eliminates ongoing dividend payments and is seen as a significant step towards enhancing the company's financial stability. CEO Joseph H. Capper expressed optimism about the company's future growth and innovation following this milestone.
Read more →MDXGMIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga.
MiMedx Group, Inc. (Nasdaq: MDXG) has announced its participation in several upcoming investor conferences, including the Craig-Hallum Capital Group's Alpha Select Conference, scheduled for November 16, 2023, and the Mizuho Medical Device & Healthcare Services Summit on December 6, 2023. These events provide an opportunity for the company's senior management to engage with investors. MiMedx aims to be a leader in providing innovative healing solutions for chronic wounds and surgical applications, reflecting its dedication to improving quality of life.
Read more →MDXGMIMEDX to Highlight Published Data at SAWC Fall
MiMedx Group, Inc. (MDXG) announced its involvement in the upcoming Symposium on Advanced Wound Care (SAWC) Fall meeting in Las Vegas, where it will sponsor a lunch symposium and exhibit at booth 511. Notable faculty will present data on skin substitutes for treating Venous Leg Ulcers and the importance of debridement in chronic wound treatment. Additionally, nine clinical posters will be displayed, showcasing the company's commitment to clinical evidence and innovation in wound care solutions.
Read more →MDXGMIMEDX Announces Third Quarter 2023 Operating and Financial Results Third Consecutive Quarter of Net Sales Growth Exceeding 20% Over the Prior Year Period Raises Full-Year 2023 Net Sales Percentage Growth Outlook to the
MIMEDX Group, Inc. announced strong financial results for the third quarter of 2023, highlighting a net sales increase of 20.7% totaling $81.7 million compared to the same period in 2022. The company raised its full-year net sales growth outlook to the high teens, bolstered by strong demand across its Wound & Surgical product lines. Additionally, MIMEDX reported an increase in Adjusted EBITDA margin, signaling operational effectiveness. However, the gross profit margin showed minimal change year-over-year, reflecting some challenges.
Read more →MDXGMIMEDX to Host Third Quarter 2023 Operating and Financial Results Conference Call on October 30
MiMedx Group, Inc. (MDXG) announced that it will report its third quarter operating and financial results on October 30, 2023. Following the results, the company will host a conference call and webcast at 4:30 p.m. ET to discuss these outcomes. The event will provide insights into the company’s performance, particularly in the wound care sector, demonstrating their ongoing commitment to innovation in healing solutions.
Read more →MDXGMIMEDX Announces Launch of EPIEFFECT™
MiMedx Group, Inc. announced the launch of EPIEFFECT™, a new addition to its Advanced Wound Care (AWC) product line aimed at treating complex wounds like diabetic foot ulcers. EPIEFFECT features a tri-layer configuration that enhances the securing of grafts and is suitable for deep or tunneling wounds. The product has been endorsed by medical professionals for its robust clinical evidence and its ability to meet specific patient needs. EPIEFFECT will be available in various sizes and is set to be included in the Medicare Part B Average Sales Price File effective October 1, 2023.
Read more →MDXGMIMEDX to Present at Upcoming Investor Conferences MARIETTA, Ga.
MiMedx Group, Inc. (MDXG) has announced its participation in several upcoming investor conferences, including the H.C. Wainwright 25th Annual Global Investment Conference and the Cantor Fitzgerald Global Healthcare Conference. The presentations will allow senior management to engage with institutional investors and highlight the company's commitment to innovative healing solutions. MiMedx focuses on providing advanced products for wound care, burns, and surgical applications, emphasizing its mission to improve the quality of life through innovation.
Read more →MDXGMIMEDX Announces Second Quarter 2023 Operating and Financial Results Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Grow
MIMEDX Group, Inc. reported strong financial results for the second quarter of 2023, achieving net sales of $81.3 million, a 21.5% increase over the same period last year. The company's net income stood at $1.2 million, and Adjusted EBITDA reached $14.1 million, reflecting positive operational momentum and increased demand in their Wound & Surgical product lines. MIMEDX has raised its full-year 2023 sales growth guidance to the mid-to-high teens percentage range, bolstered by a successful new CFO appointment. However, rising research and development costs and restructuring in the Regenerative Medicine unit present financial challenges.
Read more →MDXGMIMEDX to Host Second Quarter 2023 Operating and Financial Results Conference Call on August 1
MiMedx Group, Inc. announced it will report its second quarter 2023 operating and financial results on August 1, 2023. A conference call and webcast will follow the results announcement at 5:00 p.m. ET. The call is aimed at giving investors insights into the company's performance. MiMedx is known for its innovative solutions in wound care and is focused on restoring quality of life through its products.
Read more →MDXGMIMEDX Announces Favorable Ruling in Putative Securities Class Action Case
MiMedx Group, Inc. (MDXG) announced a favorable legal ruling where the Eleventh Circuit Court of Appeals upheld the dismissal of a securities class action lawsuit filed against the company in 2019. The lawsuit alleged violations of federal securities laws. Following the ruling, MIMEDX's General Counsel expressed optimism about the company's commitment to innovation in patient care and wound management. This decision alleviates potential legal concerns, allowing MIMEDX to focus on its growth in the healthcare market.
Read more →MDXGDocument MIMEDX Appoints Doug Rice as Chief Financial Officer Company adds seasoned MedTech CFO to leadership team MARIETTA, Ga.
MIMEDX has appointed Doug Rice as its new Chief Financial Officer, effective immediately. Rice, who has extensive experience in MedTech, previously served as CFO at Orthofix Medical and will lead the financial strategy for MIMEDX. His appointment comes as the company aims to enhance its market position and capitalize on new strategic opportunities. Rice expressed excitement about joining the team and contributing to the company's growth, following the resignation of former CFO Pete Carlson.
Read more →MDXGMIMEDX Appoints Doug Rice as Chief Financial Officer
MiMedx Group, Inc. (MDXG) has appointed Doug Rice as its new Chief Financial Officer, effective immediately. Rice brings nearly a decade of experience from Orthofix Medical and prior roles in various finance leadership positions. His appointment aligns with a promising growth trajectory for the company, which has recently reported a strong start to 2023. MiMedx also granted inducement awards to Rice, including performance stock units, restricted stock units, and stock options as part of his compensation package.
Read more →MDXGMIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business Expected to Significantly Improve Profitability Suspending Current Activities Associated with Knee Osteoarthritis Program and Disbandin
MIMEDX has announced a strategic realignment aimed at enhancing its focus on the Wound & Surgical business, which the company anticipates will substantially improve profitability. The anticipated changes could potentially add around $25 million to Adjusted EBITDA for 2023, while the company is adjusting its sales growth outlook upwards. However, the realignment entails one-time expenses of $5 million and the suspension of their knee osteoarthritis program, reflecting an adjustment to their strategic focus. MIMEDX remains committed to providing solutions for complex wound healing challenges, believing this shift will benefit both patients and shareholders.
Read more →MDXGMIMEDX Announces First Quarter 2023 Operating and Financial Results First Quarter Net Sales of $71.7 Million Reflect an Increase of 21.7% Over the Prior Year Period Revenue Growth & Cost Controls Help Drive Improvements
MIMEDX Group, Inc. reported first quarter 2023 financial results showing net sales of $71.7 million, an increase of 21.7% year-over-year. The company achieved a reduction in net loss to $5.0 million, improved gross margins, and reported an Adjusted EBITDA of $5.5 million. Strong demand for new surgical products and growth in private physician offices contributed to these results. However, investigation and related expenses added financial burdens.
Read more →MDXGMIMEDX to Host First Quarter 2023 Operating and Financial Results Conference Call on May 2
MiMedx Group, Inc. (Nasdaq: MDXG) will report its first quarter 2023 operating and financial results after market close on May 2, 2023. The senior management team will host a conference call to discuss these results starting at 5:00 p.m. Eastern Time. MiMedx focuses on placental biologics, addressing clinical needs in wound care and surgical recovery. The company is also advancing a late-stage pipeline targeting knee osteoarthritis.
Read more →MDXGMIMEDX Announces Chief Financial Officer Transition Executive Search Underway MARIETTA, Ga.
MiMedx Group, Inc. announced the departure of Chief Financial Officer Peter M. Carlson, who is leaving for other opportunities. The company is currently conducting a search for his successor, and Carlson will assist in ensuring a smooth transition. Over his three-year tenure, Carlson contributed significantly to the company's financial stability, including efforts to raise debt and equity. MiMedx continues to focus on advancing its products and pipeline in placental biologics and other healthcare sectors.
Read more →MDXGMIMEDX Comments on Recent Data Brief Published by Office of Inspector General
MiMedx Group, Inc. applauded a recent OIG report addressing compliance issues among skin substitute manufacturers regarding Medicare reimbursement. The report advocates for a transition to ASP-based payments to curb excessive costs. MIMEDX highlighted its commitment to transparent pricing with its products, EPIFIX® and EPICORD®, which align with ASP guidelines. The company supports further measures by CMS to enhance compliance and reduce financial burdens on the Medicare Trust Fund.
Read more →MDXGMIMEDX Announces Fourth Quarter and Full Year 2022 Operating and Financial Results Reports Highest Quarterly Net Sales Since the Fourth Quarter of 2019 Quarterly Net Sales of $74.4 million Reflect Growth of 10% with Stro
MiMedx Group, Inc. reported its fourth quarter and full year 2022 financial results, highlighting a 10% growth in quarterly net sales to $74.4 million, the highest since Q4 2019. The company has initiated the first of two registrational clinical trials for its micronized dehydrated human amnion/chorion membrane product aimed at treating knee osteoarthritis. Despite the positive sales growth, the company recorded a net loss of $30.2 million for the year, alongside concerns regarding the impact of Medicare reimbursement changes on future performance.
Read more →MDXGMIMEDX to Host Fourth Quarter and Full Year 2022 Operating and Financial Results Conference Call on February 28
MiMedx Group, Inc. announced it will report its operating and financial results for Q4 and the full year of 2022 on February 28, 2023. The announcement includes details about a conference call that will be hosted by senior management to review the results. The company's ongoing commitment to developing placental tissue allografts for various healthcare sectors positions it as a significant player in the industry.
Read more →MDXGMIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead
MIMEDX has appointed Joseph H. Capper as its new Chief Executive Officer and Director, effective immediately, following his successful leadership tenure in previous roles. Capper, with nearly three decades of experience in MedTech, is known for driving significant growth and creating value in healthcare companies. He aims to leverage MIMEDX's innovative product pipeline and market position to enhance patient care and achieve substantial growth. The Board has expressed strong confidence in Capper's abilities to lead the company into a promising future.
Read more →MDXGMIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on Evolving Medicare Reimbursement Landscape and Provides Corporate Updates
MiMedx Group, Inc. has confirmed its net sales expectations for the fourth quarter and full year of 2022, predicting revenues between $73 million to $76 million for Q4 and $266 million to $269 million for the full year. The company provided insight into potential Medicare reimbursement changes, which could affect its wound care products significantly. MIMEDX has made organizational changes, including headcount reductions, to cut costs and improve operational efficiency. The company continues to advocate with Medicare to ensure effective reimbursement practices that do not limit patient access to care.
Read more →MDXGDisclaimer & Cautionary Statements Some of the information and statements contained in this presentation and certain oral statements made from time to time by representatives of MIMEDX constitute "forward-looking stateme
MIMEDX provided a presentation outlining significant forward-looking statements regarding its products and market position. The company anticipates potential reimbursement policy changes from the U.S. Centers for Medicare and Medicaid Services (CMS) that may impact sales positively in 2024. Additionally, MIMEDX has initiated the international launch of its EPIFIX product in Japan, which is expected to enhance its market presence. However, the company cautions that clinical trial outcomes and regulatory approvals remain uncertain, introducing risks to its projections and timelines.
Read more →MDXGMIMEDX Announces Commercial Launch of EPIFIX in Japan with Exclusive Distribution Agreement with GUNZE MEDICAL LIMITED
MIMEDX has announced the exclusive commercial launch of EPIFIX in Japan through a partnership with Gunze Medical Limited. This collaboration positions MIMEDX advantageously in the market, leveraging Gunze's established distribution network and expertise in wound care products. EPIFIX, already approved by the Japanese Ministry of Health, is set to address the needs of patients suffering from hard-to-heal wounds such as diabetic foot ulcers and venous leg ulcers. The company aims to build on previous training efforts, engaging local clinicians and key opinion leaders to enhance the product's market presence and uptake.
Read more →MDXG▲ +6.8%on this newsshared move
MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer MIMEDX bolsters management team with 30+ year MedTech veteran with extensive operational leadership MARIETTA, Ga.
MIMEDX has appointed Ricci S. Whitlow as its new Chief Operating Officer, bringing over 30 years of experience in the MedTech field. Ms. Whitlow's role will involve leading key operational functions including manufacturing and quality assurance. Her expertise is viewed as critical for navigating the upcoming regulatory changes in placental-based products. MIMEDX aims to enhance its operations and leverage its product pipeline to better serve patients.
Read more →MDXGMIMEDX Announces Wound & Surgical Product Pipeline Expansion via In-Licensing and Distribution Agreement with Turn Therapeutics
Agreement provides MIMEDX with exclusive rights to Turn’s PermaFusion® proprietary antimicrobial intellectual property (IP), accelerating the product development pipeline for wound and surgical recovery applications MARIETTA, Ga., Dec. 08, 2022 (GLOBE NEWSWIRE) -- MiMedx Group,
Read more →MDXG▲ +5.2%on this news
A PIONEER & LEADER IN PLACENTAL BIOLOGICS Investor Presentation November 2022 Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and
Presentation November 2022 Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual r
Read more →MDXG▲ +10.7%on this news
MIMEDX to Present at Upcoming Investor Conferences
MARIETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will present at the following investor conferences: Canaccord Genuity MedTech, D
Read more →MDXG▼ -8.6%on this news
MIMEDX Announces Third Quarter 2022 Operating and Financial Results Third Quarter Net Sales of $67.7 Million Reflect Growth of 7.3% Introducing Wound & Surgical and Regenerative Medicine Segment Reporting to Highlight Tr
MIMEDX Announces Third Quarter 2022 Operating and Financial Results Third Quarter Net Sales of $67.7 Million Reflect Growth of 7.3% Introducing Wound & Surgical and Regenerative Medicine Segment Reporting to Highlight Trends Within Each Business Unit Third Quarter Growth Led b
Read more →MDXGMIMEDX to Host Third Quarter 2022 Operating and Financial Results Conference Call on November 2
MARIETTA, Ga., Oct. 19, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the third quarter ended September 30, 2022, afte
Read more →MDXGMIMEDX Appoints Matt Notarianni as Head of Investor Relations
Experienced Healthcare-focused Financial and Communications Leader to Strengthen and Expand Relationships with Investment Community MARIETTA, Ga., Oct. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biolog
Read more →MDXG▼ -5.2%on this news· ran to -15% by day 3
MIMEDX Announces Launch of AXIOFILL™
Adds a Unique Collagen Matrix Particulate Derived from Human-Placental Tissue to the Growing $1B Surgical Recovery Market MARIETTA, Ga., Sept. 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics compa
Read more →MDXGMIMEDX Announces Launch of AMNIOEFFECT™
New Product Enables Company to Target Additional Surgical Procedures and Deepen Market Penetration in the Growing $1B Surgical Recovery Market MARIETTA, Ga., Sept. 19, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational plac
Read more →MDXGMIMEDX EPIFIX Receives Reimbursement Approval in Japan
Provides Favorable Access to a New $500 Million Market for the Treatment of Refractory Diabetic and Venous Ulcers for EPIFIX – the First and Only Amniotic Tissue Product Approved for Use in Japan MARIETTA, Ga., Sept. 12, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG)
Read more →MDXGMIMEDX Announces Leadership Transition
K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today
Read more →MDXGmdxgcanaccord081022 1 A TRANSFORMATIONAL PLACENTAL BIOLOGICS COMPANY Canaccord Genuity 42nd Annual Growth Conference August 2022 2 DISCLAIMER & CAUTIONARY STATEMENTS This presentation includes forward-looking statements.
1 A TRANSFORMATIONAL PLACENTAL BIOLOGICS COMPANY Canaccord Genuity 42nd Annual Growth Conference August 2022 2 DISCLAIMER & CAUTIONARY STATEMENTS This presentation includes forward-looking statements. Statements regarding: (i) future sales or sales growth; (ii) our 2022 financia
Read more →MDXGMIMEDX to Present at the Canaccord Genuity 42nd Annual Growth Conference
MARIETTA, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will present at the Canaccord Genuity 42nd Annual Growth Conference in Boston on
Read more →MDXG▲ +7.3%on this news· ran to +22% by day 3shared move
MIMEDX Announces Second Quarter 2022 Operating and Financial Results Second Quarter Net Sales of $66.9 Million Reflects Double-Digit Revenue Increase for the Fourth Consecutive Quarter in the Company's Continuing Portfol
MIMEDX Announces Second Quarter 2022 Operating and Financial Results Second Quarter Net Sales of $66.9 Million Reflects Double-Digit Revenue Increase for the Fourth Consecutive Quarter in the Company's Continuing Portfolio of Products Achieves Strong Year-Over-Year Revenue Grow
Read more →MDXGMIMEDX Announces Formation of Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts
Scientific Advisory Board Adds Multi-disciplinary Clinical and Scientific Expertise to Support Acceleration of the Company’s mdHACM Placental Biologics Pipeline MARIETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a tran
Read more →MDXGMIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3
MARIETTA, Ga., July 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the second quarter ended June 30, 2022, after th
Read more →MDXGMIMEDX Welcomes Kate Surdez as Chief Human Resources Officer
Proven Biotech Executive Brings Versatile Leadership Experience MARIETTA, Ga., July 18, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the addition of Kate Surdez as Chief Hu
Read more →MDXG▲ +9.2%on this news
MIMEDX Engages Nordic Bioscience Clinical Development A/S to Propel Registrational Trials of Placental Biologic Injectable for Knee Osteoarthritis
Image Analysis Group to Provide Imaging Strategy and Advanced Imaging Analytics in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program MARIETTA, Ga., June 15, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational pl
Read more →MDXGMIMEDX Shareholders Vote to Approve All Proposals at the 2022 Annual Meeting
Dr. Phyllis Gardner and James L. Bierman Reelected to Board of Directors Company Also Receives Approvals for Say-on-Pay Proposal and Qualified Employee Stock Purchase Plan MARIETTA, Ga., June 07, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Compa
Read more →MDXGMIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2022 Annual Meeting of Shareholders
Deadline to Pre-Register is 9:00 a.m. Eastern Time on June 6, 2022 Pre-Registration Required to Attend Annual Meeting Visit www.votemimedx.com for Instructions on How to Pre-Register MARIETTA, Ga., June 03, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” o
Read more →MDXGMIMEDX Addresses Presentation by Prescience Point
Company Highlights Factually Accurate Information Already Provided Urges Shareholders to Vote “FOR” MIMEDX’s Highly Qualified and Independent Directors – James L. Bierman and Phyllis Gardner, M.D. On the WHITE Proxy Card Today MARIETTA, Ga., June 02, 2022 (GLOBE NEWSWIRE) -- Mi
Read more →MDXGMIMEDX Board Chair Dr. M. Kathleen Behrens Writes Letter to Fellow Shareholders
Urges Shareholders to Vote “FOR” MIMEDX’s Highly Qualified and Independent Directors – James L. Bierman and Phyllis Gardner, M.D. on the WHITE Proxy Card Today MARIETTA, Ga., May 31, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transf
Read more →MDXGMIMEDX Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns
Funding Enables Evaluation of PURION® Processed Placental Tissue as an Innovative Approach in the Management of Acute Military-Related Injuries, Addressing a Critical Unmet Need MARIETTA, Ga., May 31, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “C
Read more →MDXGDISCLAIMER & CAUTIONARY STATEMENTS This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue relian
A TRANSFORMATIONAL PLACENTAL BIOLOGICS COMPANY H.C. Wainwright Global Investment Conference May 2022 Exhibit 99.1 DISCLAIMER & CAUTIONARY STATEMENTS This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and th
Read more →MDXG▼ -7.6%on this news
MIMEDX Investor Presentation Highlights Clear Strategy for Value Creation
Decisive, Positive Actions Taken to Stabilize and Transform MIMEDX Have Established Strong, New Foundation for Growth Company Urges Shareholders to Vote “FOR” Both Highly Qualified Director Nominees – James L. Bierman and Phyllis Gardner, M.D. – on the WHITE Proxy Card MARIETTA
Read more →MDXGMIMEDX Mails Letter to Shareholders
Highlights Successful Execution of Transformation Strategy Under CEO Tim Wright Reaffirms Commitment to Enhancing Value for ALL Shareholders Urges Shareholders to Vote “FOR” Both of MIMEDX’s Highly Qualified Director Nominees – James L. Bierman and Phyllis Gardner, M.D. – on th
Read more →MDXG▼ -5.6%on this newsshared move
MIMEDX Comments on Prescience Point’s False and Misleading Statements
Cautions Shareholders Not to Let Prescience Point Unravel MIMEDX’s Transformation Urges Shareholders to Protect their Investments by Voting “FOR” Dr. Phyllis Gardner and James L. Bierman Highlights Prescience Point’s and Eiad Asbahi’s True Agenda MARIETTA, Ga., May 09, 2022 (G
Read more →MDXG▼ -10.9%on this news· ran to -21% by day 3shared move
MIMEDX to Participate at Upcoming Investor Conferences
MARIETTA, Ga., May 05, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will participate in the following investor conferences: Bank of America Securitie
Read more →MDXG▲ +7.3%on this newsshared move
MIMEDX Announces First Quarter 2022 Operating and Financial Results First Quarter Net Sales of $58.9 Million Reflects Double-Digit Revenue Increase for the Third Straight Quarter in the Company's Continuing Portfolio of
MIMEDX Announces First Quarter 2022 Operating and Financial Results First Quarter Net Sales of $58.9 Million Reflects Double-Digit Revenue Increase for the Third Straight Quarter in the Company's Continuing Portfolio of Products Management to Host Conference Call on May 4, 2022
Read more →MDXGMIMEDX Comments on Prescience Point's Recent Filing Shareholders Urged to Support MIMEDX Board MARIETTA, Ga.
MIMEDX Comments on Prescience Point's Recent Filing Shareholders Urged to Support MIMEDX Board MARIETTA, Ga. April 29, 2022 - MIMEDX Group, Inc. (NASDAQ MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today issued the following statement in re
Read more →MDXGMIMEDX to Host First Quarter 2022 Operating and Financial Results Conference Call on May 4
MARIETTA, Ga., April 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the first quarter ended March 31, 2022 after th
Read more →MDXG▼ -5.2%on this news
MIMEDX to Present Health Economics Clinical Data for EPIFIX in Treatment of Lower Extremity Diabetic Ulcers at SAWC Spring
Company to Sponsor Symposium and Present Three Poster Abstracts MARIETTA, Ga., April 05, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced it will sponsor a lunch symposium at t
Read more →MDXGMIMEDX to Present at the Canaccord Genuity Musculoskeletal Conference
MARIETTA, Ga., March 15, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will pr
Read more →MDXGMIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results Fourth Quarter Net Sales of $67.4 M illion and Full Year 2021 Net Sales of $258.6 M illion Reflects a Double-Digit Revenue Increase in th
MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results Fourth Quarter Net Sales of $67.4 Million and Full Year 2021 Net Sales of $258.6 Million Reflects a Double-Digit Revenue Increase in the Company's Continuing Portfolio of Products Vibrant Commer
Read more →MDXGMIMEDX to Host Fourth Quarter 2021 Operating and Financial Results Conference Call on February 28
MARIETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the fourth quarter ended December 31, 2021 after
Read more →MDXG▲ +7.3%on this news
MIMEDX Announces Dismissal of Putative Securities Class Action Lawsuit
MARIETTA, Ga., Jan. 28, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that a federal court in Georgia has denied a motion to reconsider the dismissal of Carpenters Pension Fu
Read more →MDXGMIMEDX Outlines Key Strategic Milestones for 2022
MIMEDX Primed to Commence Pivotal Phase 3 Clinical Study Program of micronized dehydrated Human Amnion Chorion Membrane (mdHACM) in Knee Osteoarthritis (KOA), Targeting Potential Late-2026 Commercial Launch Double-Digit Growth Objective in 2022 to be Driven by Treatment Transfor
Read more →MDXGMIMEDX to Participate at the H.C. Wainwright BioConnect Virtual Conference
MARIETTA, Ga., Jan. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B
Read more →MDXGMIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference
MARIETTA, Ga., Dec. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will pre
Read more →MDXGMIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day
Company to Share Probability Values from its Knee Osteoarthritis (KOA) Study; Analyses Conducted Support Confidence in Initiation of Confirmatory Phase 3 Trials in 2022 Commercial Business Strategy Demonstrates Sustainable Double-digit Growth Potential in Multiple Underpenetrate
Read more →MDXGMIMEDX Announces Speakers for December 7 Investor Day
Company to Host Virtual Event on December 7, 2021 Beginning at 9:00 a.m. ET MARIETTA, Ga., Nov. 30, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, to
Read more →MDXGMIMEDX to Present at the Piper Sandler 33rd Annual Healthcare Conference
MARIETTA, Ga., Nov. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, and Rohit Kash
Read more →MDXG▲ +15.1%on this news
MIMEDX Announces Third Quarter 2021 Operating and Financial Results Third Quarter Net Sales of $63.1 Million Versus $64.3 Million in 3Q20 Adjusted Net Sales of $62.8 Million Include a 13% Increase in Core Portfolio Sales
MIMEDX Announces Third Quarter 2021 Operating and Financial Results Third Quarter Net Sales of $63.1 Million Versus $64.3 Million in 3Q20 Adjusted Net Sales of $62.8 Million Include a 13% Increase in Core Portfolio Sales Versus 3Q20 Year-to-Date Adjusted Net Sales Increase of
Read more →MDXGMIMEDX to Host Third Quarter 2021 Operating and Financial Results Conference Call on November 3
MARIETTA, Ga., Oct. 20, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report operating and financial results for the thi
Read more →MDXGMIMEDX to Host Virtual Investor Day on December 7, 2021
MARIETTA, Ga., Oct. 14, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will host a virtual Investor Day on Tuesday, December 7
Read more →MDXG▼ -59.6%on this news
MIMEDX Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue Technology
Phase 2B Knee Osteoarthritis (KOA) Study Top-line Interim Results Demonstrate Varied Efficacy Signals between Patient Cohorts Company to Pursue Phase 3 KOA Confirmatory Studies Initial Review of Phase 3 Plantar Fasciitis Trial Data Does Not Support a Biologics License Applicati
Read more →MDXGMIMEDX Announces Effectiveness of Shelf Registration Statement
MARIETTA, Ga., Sept. 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the shelf registration statement on Form S-3 on file with the
Read more →MDXGMIMEDX to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
MARIETTA, Ga., Sept. 07, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carl
Read more →MDXGMIMEDX Announces Filing of Shelf Registration Statement with Securities and Exchange Commission
S-3 Eligibility Enabled by Accomplishment of Multiple Financial Milestones MARIETTA, Ga., Aug. 27, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, tod
Read more →MDXG▲ +6.1%on this news
MIMEDX Promotes Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs
Promotion Recognizes Skilled Leadership and Contributions to MIMEDX’s Continued Growth MARIETTA, Ga., Aug. 12, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative m
Read more →MDXGMIMEDX Announces Second Quarter 2021 Operating and Financial Results
Second Quarter Net Sales Increase 27% to $68.2 million Versus Q2 2020 On Track to Deliver Topline Results for Late-Stage Musculoskeletal Pipeline in Late Summer Company to Host Conference Call on August 4, 2021, at 8:30 AM ET MARIETTA, Ga., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Mi
Read more →MDXG▲ +11.7%on this news
MIMEDX to Host Second Quarter 2021 Operating and Financial Results Conference Call on August 4
MARIETTA, Ga., July 20, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report operating and financial results for the sec
Read more →MDXGMIMEDX Joins Russell 3000 and 2000 Indexes
MARIETTA, Ga., June 28, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today confirmed that FTSE Russell will add the Company’s common stock to its br
Read more →MDXGADVANCING REGENERATIVE MEDICINE TREATMENT THROUGH PLACENTAL SCIENCE Raymond James Human Health Innovation Conference
SCIENCE Raymond James Human Health Innovation Conference June 23, 2021 1Exhibit 99.1 ADVANCING REGENERATIVE MEDICINE TREATMENT THROUGH PLACENTAL SCIENCE Raymond James Human Health Innovation Conference June 23, 2021 1 DISCLAIMER & CAUTIONARY STATEMENTS Important Cautionary State
Read more →MDXGMIMEDX to Present at the Raymond James 2021 Human Health Innovation Conference
MARIETTA, Ga, June 16, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlso
Read more →MDXGMIMEDX Receives Regulatory Approval to Commercialize EPIFIX in Japan
Availability of EPIFIX Allografts Expected Early 2022 Approval Makes it Possible to Bring EPIFIX’s Healing Properties to as Many as 100,000 New Patients Annually MARIETTA, Ga., June 08, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an i
Read more →MDXGMIMEDX to Participate at the Jefferies Virtual Healthcare Conference
MARIETTA, Ga., May 27, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlso
Read more →MDXGMIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2021 Annual Meeting of Shareholders Deadline to Pre-Register Extended to
MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual 2021 Annual Meeting of Shareholders Deadline to Pre-Register Extended to May 26, 2021 at 10 00 a.m. Eastern Pre-Registration Required to Attend Annual Meeting Visit www.votemimedx.com for Instructions on How
Read more →MDXGDisclaimer & Cautionary Statements Important Cautionary Statement This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investo
Advancing regenerative Medicine treatment through placental science Bank of America Securities 2021 Virtual Healthcare Conference May 13, 2021 Exhibit 99.1 Disclaimer & Cautionary Statements Important Cautionary Statement This presentation includes forward-looking statements.
Read more →MDXGMIMEDX Reminds Shareholders to Vote at the Upcoming Annual Meeting
Vote FOR MIMEDX’s Experienced and Highly Qualified Directors and Governance Enhancement Proposals MARIETTA, Ga., May 12, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for rege
Read more →MDXGMIMEDX Announces Collaborative Agreement with the Wake Forest Institute for Regenerative Medicine
Relationship Furthers Mutual Interest in the Development and Advancement of Scientific Evidence to Support Safe and Effective Clinical Therapies MARIETTA, Ga., May 06, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in u
Read more →MDXGMIMEDX Urges Shareholders to Consider Prescience Point’s Motivations Before Voting Their Shares at the Company’s Annual Meeting
Questions Every Shareholder Should Ask Prescience Point Prescience Point’s Trading History Tells the Real Story MARIETTA, Ga., May 04, 2021 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a pl
Read more →MDXGMIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders Urges Shareholders to Vote the WHITE Proxy Card "FOR AL
MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders Urges Shareholders to Vote the WHITE Proxy Card "FOR ALL" Four of MIMEDX's Director Nominees - Dr. Kathleen Behre
Read more →MDXGMiMedx Announces First Quarter 2021 Financial and Operating Results First Quarter Net Sales of $60.0 Million Advancing Innovative Late-Stage Musculoskeletal Pipeline with Data Readouts Expected in Q3 2021 Company to Host
MiMedx Announces First Quarter 2021 Financial and Operating Results First Quarter Net Sales of $60.0 Million Advancing Innovative Late-Stage Musculoskeletal Pipeline with Data Readouts Expected in Q3 2021 Company to Host Conference Call on April 29, 2021 at 8:30 AM ET MARIETT
Read more →MDXGMiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs
Accomplished Regulatory Leader Joins MiMedx Management Team MARIETTA, Ga., April 28, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced t
Read more →MDXGMiMedx to Host First Quarter 2021 Operating and Financial Results Conference Call on April 29
MARIETTA, Ga., April 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report financial results for the first quarter en
Read more →MDXGMiMedx Announces Last Patients Last Visits in Three Late-Stage Musculoskeletal Trials with Proprietary Tissue Technology Advances Potential for Use of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) as a Saf
MiMedx Announces Last Patients Last Visits in Three Late-Stage Musculoskeletal Trials with Proprietary Tissue Technology Advances Potential for Use of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) as a Safe and Effective Treatment Option On Track to Advance Plann
Read more →MDXGMiMedx Confirms Receipt of Director Nominations from Prescience Point Capital Management
No Shareholder Action Required at This Time MARIETTA, Ga., April 16, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today confirmed that Prescience Poin
Read more →MDXGMiMedx Awarded Amniotic Tissue Supplier Agreement with Premier Inc.’s SURPASS™ Purchasing Program
MARIETTA, Ga., March 30, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today announced that the Company has been awarded a Group Purchasing Agreement fo
Read more →MDXGIMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Actual results may differ materially. Investors are cautioned against placing undue reliance on these statements. All statements relat
INNOVATING TREATMENTS THROUGH ADVANCED PLACENTAL SCIENCE March 9-10, 2021 2021 H.C. Wainwright & Co. Global Life Sciences Conference Exhibit 99.1 IMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Actual results may differ materially. Investo
Read more →MDXGMiMedx Announces Fourth Quarter and Full Year 2020 Financial and Operating Results Fourth Quarter Net Sales of $68.5 million, Full Year 2020 Net Sales of $248.2 million Company to Host Conference Call on
MiMedx Announces Fourth Quarter and Full Year 2020 Financial and Operating Results Fourth Quarter Net Sales of $68.5 million, Full Year 2020 Net Sales of $248.2 million Company to Host Conference Call on March 9, 2021 at 9 30 AM ET MARIETTA, Ga., March 8, 2021 -- MiMedx Group,
Read more →MDXGMiMedx Announces Appointment of Phyllis Gardner, M.D. to Board of Directors
Noted biopharmaceutical thought leader adds academic, research and industry expertise MARIETTA, Ga., March 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medi
Read more →MDXGMiMedx to Participate at Upcoming Investor Conferences
MARIETTA, Ga., March 03, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will be participating in the following virtual investor
Read more →MDXGMiMedx to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call on March 9
MARIETTA, Ga., March 02, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it will report financial results for the fourth quarter and full ye
Read more →MDXGMiMedx to Participate at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
MARIETTA, Ga., Feb. 10, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Ch
Read more →MDXGINNOVATING TREATMENTS THROUGH ADVANCED PLACENTAL SCIENCE January 11-14, 2021 2021 J.P. Morgan 39th Annual Healthcare Conference 1 IMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Inve
January 11-14, 2021 2021 J.P. Morgan 39th Annual Healthcare Conference 1Exhibit 99.1 INNOVATING TREATMENTS THROUGH ADVANCED PLACENTAL SCIENCE January 11-14, 2021 2021 J.P. Morgan 39th Annual Healthcare Conference 1 IMPORTANT CAUTIONARY STATEMENT This presentation contains forwa
Read more →MDXGMiMedx to Participate at the H.C. Wainwright BioConnect 2021 Conference
MARIETTA, Ga., Jan. 04, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Dr. Robert Stein, Ex
Read more →MDXGMiMedx to Present at the 39th Annual J.P. Morgan Healthcare Conference
MARIETTA, Ga., Dec. 07, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will present at the 39th Annual J.P. Morgan Healthcare Co
Read more →MDXGMiMedx Appoints Jack Howarth as Senior Vice President, Investor Relations
Experienced Healthcare Executive Will Expand Company’s Visibility Within the Financial Community MARIETTA, Ga., Dec. 01, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics
Read more →MDXGMiMedx To Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
MARIETTA, Ga., Nov. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Ch
Read more →MDXGIMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Investors are cautioned against placing undue reliance on these statements. All statements relating to events or results that may occu
WELCOME TO 2020 ANNUAL SHAREHOLDERS MEETING NOVEMBER 20, 2020 Exhibit 99.1 IMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Investors are cautioned against placing undue reliance on these statements. All statements relating to events or res
Read more →MDXGMiMedx To Host Virtual 2020 Annual Meeting of Shareholders on Friday, November 20
MARIETTA, Ga., Nov. 13, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today provided additional information about its upcoming virtual 2020 Annual Meeting of S
Read more →MDXGMiMedx To Present At Canaccord Genuity Virtual MedTech & Diagnostics Forum
MARIETTA, Ga., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carl
Read more →MDXGMiMedx Announces Third Quarter 2020 Financial Results Third Quarter Net Sales of $64.3 Million, Above Preliminary Range Common Stock Relisted on The Nasdaq Stock Market Under the Ticker Symbol "MDXG" Company to Host Conf
MiMedx Announces Third Quarter 2020 Financial Results Third Quarter Net Sales of $64.3 Million, Above Preliminary Range Common Stock Relisted on The Nasdaq Stock Market Under the Ticker Symbol "MDXG" Company to Host Conference Call on November 5, 2020 at 8 30 AM ET MARIETTA,
Read more →MDXGMiMedx To Advance the Conversation of Study Bias in the Clinical Evaluation of Skin Substitutes in Chronic Wounds at SAWC FALL
Company to Showcase Newly Launched EpiCord Expandable Product Line MARIETTA, Ga., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and a therapeutic biologics company, announced it will spo
Read more →MDXGMiMedx Announces Largest U.S. Commercial Payor Will Provide Coverage for EpiFix in the Treatment of Diabetic Foot Ulcers
Only Amniotic Product Covered Under Updated Commercial Policy MARIETTA, Ga., Nov. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that th
Read more →MDXGMiMedx Shares to Commence Trading on Nasdaq on Wednesday, November 4, 2020
MARIETTA, Ga., Nov. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today confirmed that the Company’s common stock will commence trading on The Nasdaq Sto
Read more →MDXGMiMedx Announces Relisting on Nasdaq MARIETTA, Ga.
MiMedx Announces Relisting on Nasdaq MARIETTA, Ga., October 30, 2020 -- MiMedx Group, Inc. (OTC PINK MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and a therapeutic biologics company, today announced that The Nasdaq Stock Market LLC has approved Mi
Read more →MDXGMiMedx Announces Relisting on Nasdaq
MARIETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that The Nasdaq Stock Market LLC has approved MiMedx’s application for
Read more →MDXGMiMedx to Host Third Quarter 2020 Financial Results Call on November 5
MARIETTA, Ga., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it will report financial results for the third quarter ended Septe
Read more →MDXGUNITED STATES DISTRICT COURT NORTHERN DISTRICT OF GEORGIA ATLANTA DIVISION IN RE MIMEDX GROUP, INC. SHAREHOLDER DERIVATIVE LITIGATION Lead Case No. 1 18-cv-04486-WMR (Consolidated with Case No. 1 18-cv-04514-WMR and Case
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF GEORGIA IN RE MIMEDX GROUP, INC. SHAREHOLDER DERIVATIVE LITIGATION Lead Case No. 1 18-cv-04486-WMR (Consolidated with Case No. 1 18-cv-04514-WMR and Case No. 1 18-cv-04864-WMR) This Document Relates To ALL ACTIONS. NOTICE OF P
Read more →MDXGMiMedx Files Definitive Proxy Materials
MARIETTA, Ga., Oct. 15, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it has filed a definitive proxy statement with the U.S. Securities
Read more →MDXGMiMedx Announces Preliminary Third Quarter 2020 Net Sales
Third Quarter 2020 Net Sales Expected to be Between $61 Million - $64 Million Latest Corporate Presentation Filed with SEC and Posted to IR Website 2020 Annual Meeting of Shareholders to be Held on November 20, 2020 MARIETTA, Ga., Sept. 21, 2020 (GLOBE NEWSWIRE) -- MiMedx Grou
Read more →MDXGMiMedx Concludes Enrollment for Phase 2B Study of Osteoarthritis (OA) of the Knee Research Advances Understanding of Amniotic Tissue as Potential Unique Treatment for Painful Chronic Condition that Affects 242 Million Pe
MiMedx Concludes Enrollment for Phase 2B Study of Osteoarthritis (OA) of the Knee Research Advances Understanding of Amniotic Tissue as Potential Unique Treatment for Painful Chronic Condition that Affects 242 Million People Globally MARIETTA, Ga., September 21, 2020 MiMedx Gr
Read more →MDXGMiMedx Concludes Enrollment for Phase 3 Plantar Fasciitis Trial Research in Plantar Fasciitis Advances Understanding of Amniotic Tissue as Potential Treatment for Chronic Musculoskeletal Pain and Function Disorders MARIE
MiMedx Concludes Enrollment for Phase 3 Plantar Fasciitis Trial Research in Plantar Fasciitis Advances Understanding of Amniotic Tissue as Potential Treatment for Chronic Musculoskeletal Pain and Function MARIETTA, Ga., September 17, 2020 MiMedx Group, Inc. (OTC PINK: MDXG) ( M
Read more →MDXGMiMedx Launches EpiCord Expandable Placental Allograft as Addition to Market Leading Portfolio
New Allograft Expands to Twice its Size and Provides a Protective Structure to Support the Wound Healing Cascade MARIETTA, Ga., Sept. 14, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an em
Read more →MDXGDISCLAIMER This presentation contains summarized information concerning the Company and the Company's business operations. All statements relating to events or results that may occur in the future are forward-looking sta
WELCOME TO 2019 ANNUAL SHAREHOLDERS MEETING AUGUST 31, 2020 Exhibit 99.1 DISCLAIMER This presentation contains summarized information concerning the Company and the Company's business operations. All statements relating to events or results that may occur in the future are for
Read more →MDXGMiMedx to Discuss Strategic Priorities at Upcoming Virtual 2019 Annual Meeting of Shareholders
MARIETTA, Ga., Aug. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today provided additional information about its upcoming virtual 2019 Annual
Read more →MDXGMiMedx Welcomes Robert B. Stein, M.D., Ph.D., to Head Revitalized R&D Efforts Pharmaceutical and Biotech Executive to Focus on Product and Pipeline Development Priorities MARIETTA, Ga.
MiMedx Welcomes Robert B. Stein, M.D., Ph.D., to Head Revitalized R&D Efforts Pharmaceutical and Biotech Executive to Focus on Product and Pipeline Development Priorities MARIETTA, Ga., August 10, 2020 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the Company ), an industry l
Read more →MDXGMiMedx Files Second Quarter 2020 Form 10-Q
Second Quarter Net Sales of $53.6 million Results Reflects Tight Cost Containment Efforts Company to Host Shareholder Update Call on August 11, 2020 MARIETTA, Ga., Aug. 04, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry le
Read more →MDXGMiMedx Adds Rohit Kashyap, Ph.D., to Leadership Team as Executive Vice President and Chief Commercial Officer Strategic Leader with Proven Record of Delivering Growth and Business Transformation MARIETTA, Ga.
MiMedx Adds Rohit Kashyap, Ph.D., to Leadership Team as Executive Vice President and Chief Commercial Officer Strategic Leader with Proven Record of Delivering Growth and Business Transformation MARIETTA, Ga., July 28, 2020 -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "
Read more →MDXGMiMedx Announces Filing of 2020 First Quarter Form 10-Q
Company Now Caught Up in Financial Reporting First Quarter Net Sales of $61.7 million MARIETTA, Ga., July 06, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologic
Read more →MDXGMiMedx Announces Filing of 2019 Annual Report
Annual Report on Form 10-K includes Audited Financial Results for 2019 Transition to Revenue Recognition on an “As-Shipped” Basis Reflects Improved Internal Control Environment MARIETTA, Ga., July 06, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “th
Read more →MDXGMiMedx Announces Filing of 2019 Annual Report Annual Report on Form 10-K includes Audited Financial Results for 2019 Transition to Revenue Recognition on an As-Shipped Basis Reflects Improved Internal Control Environment
MiMedx Announces Filing of 2019 Annual Report Annual Report on Form 10-K includes Audited Financial Results for 2019 Transition to Revenue Recognition on an As-Shipped Basis Reflects Improved Internal MARIETTA, Ga., July 6, 2020 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or
Read more →MDXGMiMedx Announces Concurrent $150 Million Private Equity and Debt Financings
Equity Financing Led by EW Healthcare Partners and Debt Financing Provided by Hayfin Capital Management EW Healthcare Partners Managing Director and Co-Founder Martin Sutter and Former Medtronic Chairman and CEO William Hawkins to Join MiMedx Board of Directors MARIETTA, Ga., J
Read more →MDXGMiMedx Provides Update on Payment Protection Program Loan Company Is Repaying Loan in Full Marietta, GA.
MiMedx Provides Update on Payment Protection Program Loan Company Is Repaying Loan in Full Marietta, GA., May 8, 2020 - MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, toda
Read more →MDXGMiMedx Announces Appointment of William L. Phelan as Chief Accounting Officer Marietta, GA.
MiMedx Announces Appointment of William L. Phelan as Chief Accounting Officer Marietta, GA., May 5, 2020 - MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced th
Read more →MDXGMiMedx Announces Additional Access to Capital and Financing Includes Approval of Paycheck Protection Program Loan and Agreement to Modify Term Loan Marietta, GA.
MiMedx Announces Additional Access to Capital and Financing Includes Approval of Paycheck Protection Program Loan and Agreement to Modify Term Loan Marietta, GA., April 21, 2020 - MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced w
Read more →MDXGMiMedx Announces Settlement of VA Pricing Investigation Settlement Recognizes Company's Cooperation & Voluntary Disclosure MARIETTA, Ga.
MiMedx Announces Settlement of VA Pricing Investigation Settlement Recognizes Company's Cooperation & Voluntary Disclosure MARIETTA, Ga., April 6, 2020 -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging
Read more →MDXGMiMedx Names Peter M. Carlson as Chief Financial Officer Marietta, GA.
MiMedx Names Peter M. Carlson as Chief Financial Officer Marietta, GA., March 19, 2020 - MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that Peter M. Carlso
Read more →MDXGMiMedx Announces Filing of 2018 Annual Report Annual Report on Form 10-K includes Audited Financial Results for 2016 (restated), 2017 and 2018 2018 Net Sales of $359.1 million Reflects Revenue Recognition on Cash Basis f
MiMedx Announces Filing of 2018 Annual Report Annual Report on Form 10-K includes Audited Financial Results for 2016 (restated), 2017 and 2018 2018 Net Sales of $359.1 million Reflects Revenue Recognition on Cash Basis for all Years MARIETTA, Ga., March 17, 2020 -- MiMedx Gro
Read more →MDXGMiMedx Provides Update Regarding Timing of Restatement Company Expects to File 2018 Annual Report on Form 10-K in Early 2020 MARIETTA, Ga.
MiMedx Provides Update Regarding Timing of Restatement Company Expects to File 2018 Annual Report on Form 10-K in Early 2020 MARIETTA, Ga., December 12, 2019 -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an eme
Read more →MDXGMiMedx Announces Resignation of Board Member Mr. Luis A. Aguilar Resigned Effective
MiMedx Announces Resignation of Board Member Mr. Luis A. Aguilar Resigned Effective September 19, 2019 MARIETTA, Ga., September 20, 2019 -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or "the Company"), an industry leader in advanced wound care and an emerging therapeutic bio
Read more →MDXGMiMedx Announces Agreement Regarding 2019 and 2020 Shareholder Meetings MARIETTA, Ga.
MiMedx Announces Agreement Regarding 2019 and 2020 Shareholder Meetings MARIETTA, Ga., August 8, 2019 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the Company ), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced an agree
Read more →MDXGMiMedx Urges Shareholders to Vote Today FOR All of the Board s Highly Qualified Nominees on the BLUE Proxy Card The MiMedx Annual Meeting is This Coming Monday
MiMedx Urges Shareholders to Vote Today FOR All of the Board s Highly Qualified Nominees on the BLUE Proxy Card The MiMedx Annual Meeting is This Coming Monday, June 17, 2019 MARIETTA, Ga., June 14, 2019 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the Company ), an industr
Read more →MDXGMiMedx Highlights Skills and Experience of Director Nominees Company Urges Shareholders to Vote with the BLUE Card Online or By Phone Today MARIETTA, Ga.
MiMedx Highlights Skills and Experience of Director Nominees Company Urges Shareholders to Vote with the BLUE Card Online or By Phone Today MARIETTA, Ga., June 13, 2019 -- MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the Company ), an industry leader in advanced wound care
Read more →MDXGLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS and Egan-Jones in Recommending MiMedx Shareholders Vote For All Three of the Company s Director Nominees Glass Lewis and ISS Recommend Shareholders Vote AGAIN
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS and Egan-Jones in Recommending MiMedx Shareholders Vote For All Three of the Company s Director Nominees Glass Lewis and ISS Recommend Shareholders Vote AGAINST the Two Shareholder Proposals Submitted by Parker H. P
Read more →MDXGLeading Independent Proxy Advisory Firms ISS and Egan-Jones Recommend That MiMedx Shareholders Vote the BLUE Card FOR All Three of the Company s Director Nominees ISS Recommends Shareholders Vote AGAINST the Petit Group
Leading Independent Proxy Advisory Firms ISS and Egan-Jones Recommend That MiMedx Shareholders Vote the BLUE Card FOR All Three of the Company s Director Nominees ISS Recommends Shareholders Vote AGAINST the Petit Group s Shareholder Proposals ISS Recommends Shareholders Do No
Read more →MDXGMiMedx Issues Additional Information to Shareholders Company Urges Shareholders to Vote the BLUE Card Today MARIETTA, Ga.
MiMedx Issues Additional Information to Shareholders Company Urges Shareholders to Vote the BLUE Card Today MARIETTA, Ga., June 10, 2019 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the Company ), an industry leader in advanced wound care and an emerging therapeutic biologi
Read more →MDXGMiMedx Issues New Presentation for Investors in Advance of 2018 Annual Meeting Illustrates Key Events and Steps the Board Has Taken in Response to Allegations of Misconduct by Certain Members of the Company s Former Mana
MiMedx Issues New Presentation for Investors in Advance of 2018 Annual Meeting Illustrates Key Events and Steps the Board Has Taken in Response to Allegations of Misconduct by Certain Members of the Company s Former Management, Including Former Chairman and CEO Parker H. Pete P
Read more →MDXGMiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point Six New Directors to Join the Board Dr. M. Kathleen Behrens Wilsey to be Named Chairwoman of the Board Refreshment Comes After Au
MiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point Six New Directors to Join the Board Dr. M. Kathleen Behrens Wilsey to be Named Chairwoman of the Board Refreshment Comes After Audit Committee Concludes its Independent Investigation an
Read more →MDXGMiMedx Announces BDO as the Company s New Independent Registered Public Accounting Firm Marks Important Step in Advancement of Company s Financial Restatement Process MARIETTA, Ga.
MiMedx Announces BDO as the Company s New Independent Registered Public Accounting Firm Marks Important Step in Advancement of Company s Financial Restatement Process MARIETTA, Ga., May 28, 2019 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the Company ), an industry leader i
Read more →MDXGMiMedx Announces Conclusion of Audit Committee s Independent Investigation Investigation Revealed Extensive Misconduct by Former Senior Management MARIETTA, Ga.
MiMedx Announces Conclusion of Audit Committee s Independent Investigation Investigation Revealed Extensive Misconduct by Former Senior Management MARIETTA, Ga., May 23, 2019 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the Company ), an industry leader in advanced wound ca
Read more →MDXGMiMedx Appoints Timothy R. Wright as Chief Executive Officer Healthcare Industry Veteran to Lead Next Phase of MiMedx MARIETTA, Ga.
MiMedx Appoints Timothy R. Wright as Chief Executive Officer Healthcare Industry Veteran to Lead Next Phase of MiMedx MARIETTA, Ga., May 9, 2019 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the Company ), an industry leader in advanced wound care and an emerging therapeutic
Read more →MDXGMiMedx Announces Board Approval of Long-Range Strategic Plan Organization Focused on Execution of 2019 Priorities Provides Update on Investigation and Other Matters MARIETTA, Ga.
MiMedx Announces Board Approval of Long-Range Strategic Plan Organization Focused on Execution of 2019 Priorities Provides Update on Investigation and Other Matters MARIETTA, Ga., April 11, 2019 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the Company ), an industry leader
Read more →MDXGMIMEDX ANNOUNCES ORGANIZATIONAL REALIGNMENT PROGRAM Plan Will Improve Cost Structure and is Designed to Position Business for Long-Term Success Marietta, Georgia
MIMEDX ANNOUNCES ORGANIZATIONAL REALIGNMENT PROGRAM Plan Will Improve Cost Structure and is Designed to Position Business for Long-Term Success Marietta, Georgia, December 5, 2018 MiMedx Group, Inc. (OTC PINK: MDXG), a leading developer and marketer of regenerative and therape
Read more →MDXGMIMEDX ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN IN RESPONSE TO DELISTING FROM NASDAQ Marietta, Georgia
MIMEDX ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN IN RESPONSE TO DELISTING FROM NASDAQ Marietta, Georgia, November 7, 2018 MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that its Board of Dire
Read more →MDXGMIMEDX RECEIVES NASDAQ DELISTING NOTIFICATION Company Remains Focused on Delivering Operational and Clinical Success Shares Will Continue to Trade Publicly on the Over the Counter Market Marietta, Georgia
MIMEDX RECEIVES NASDAQ DELISTING NOTIFICATION Company Remains Focused on Delivering Operational and Clinical Success Shares Will Continue to Trade Publicly on the Over the Counter Market Marietta, Georgia, November 7, 2018 MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer
Read more →MDXGMIMEDX ANNOUNCES NASDAQ LISTING EXTENSION Marietta, Georgia
MIMEDX ANNOUNCES NASDAQ LISTING EXTENSION Marietta, Georgia, September 20, 2018 MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that a Nasdaq Hearings Panel (the Panel ) has granted the Company s req
Read more →MDXGMIMEDX PROVIDES UPDATE ON PREVIOUSLY ANNOUNCED SENIOR EXECUTIVE SEPARATIONS Board and Compensation Committee Determine That Separations Be Treated as For Cause Terminations Based on Information from Audit Committee s Ong
MIMEDX PROVIDES UPDATE ON PREVIOUSLY ANNOUNCED SENIOR EXECUTIVE SEPARATIONS Board and Compensation Committee Determine That Separations Be Treated as For Cause Terminations Based on Information from Audit Committee s Ongoing Independent Investigation Parker H. Petit Resigns as
Read more →MDXGMIMEDX ANNOUNCES RECEIPT OF NASDAQ LETTER Company Will Request Hearing with Nasdaq Hearings Panel Marietta, Georgia
MIMEDX ANNOUNCES RECEIPT OF NASDAQ LETTER Company Will Request Hearing with Nasdaq Hearings Panel Marietta, Georgia, July 26, 2018 MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today provided an update concerning
Read more →MDXGMIMEDX ANNOUNCES LEADERSHIP CHANGES AND CORPORATE ACTIONS Pete Petit Resigns as Chairman and Chief Executive Officer Charles Evans Appointed Chairman of the Board Bill Taylor Resigns as President and Chief Operating Offi
MIMEDX ANNOUNCES LEADERSHIP CHANGES AND CORPORATE ACTIONS Marietta, Georgia, July 2, 2018 The Board of Directors of MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that Parker H. Pete Petit has resig
Read more →MDXGMIMEDX REPORTS UNREVIEWED FIRST QUARTER REVENUE EXCEEDS UPPER END OF ITS GUIDANCE COMPANY ANNOUNCES ITS REVENUE GUIDANCE FOR SECOND QUARTER AND INCREASES FULL YEAR REVENUE GUIDANCE Marietta, Georgia
MIMEDX REPORTS UNREVIEWED FIRST QUARTER REVENUE EXCEEDS UPPER END OF ITS GUIDANCE COMPANY ANNOUNCES ITS REVENUE GUIDANCE FOR SECOND QUARTER AND INCREASES FULL YEAR REVENUE GUIDANCE Marietta, Georgia, April 26, 2018 -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and m
Read more →MDXGMIMEDX SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against MiMedx Group Inc. - MDXG
NEW ORLEANS, April 13, 2018 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 25, 2018 to file lead plaintiff applications in securities class action lawsuits against MiMedx Group Inc. (Nasdaq:MDXG), if they pur
Read more →MDXGMIMEDX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against MiMedx Group Inc. - MDXG
NEW ORLEANS, April 06, 2018 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 25, 2018 to file lead plaintiff applications in securities class action lawsuits
Read more →MDXGMIMEDX GROUP LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In MiMedx Group, Inc. To Contact The Firm
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ:MDXG) of the April 25, 2018 deadline to seek the role of lead plaintiff in a federal securities c
Read more →MDXGMiMedx Announces Expectation to Exceed the $92 Million Top End of First Quarter Revenue Guidance Continues to Cooperate with Regulatory Agencies Marietta, Georgia
MiMedx Announces Expectation to Exceed the $92 Million Top End of First Quarter Revenue Guidance Continues to Cooperate with Regulatory Agencies Marietta, Georgia, March 15, 2018 -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therape
Read more →MDXGMiMedx Receives Notice of Filing Delinquency from NASDAQ Marietta, Georgia
MiMedx Receives Notice of Filing Delinquency from NASDAQ Marietta, Georgia, March 2, 2018 -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today received written notification from the NASDAQ Stock Market that the C
Read more →MDXGMiMedx Postpones Release of its Fourth Quarter and Fiscal Year 2017 Financial Results Marietta, Georgia
MiMedx Postpones Release of its Fourth Quarter and Fiscal Year 2017 Financial Results Marietta, Georgia, February 20, 2018 -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it will postpone the
Read more →MDXGMichael Senken Phone: (770) 651-9100 MiMedx Releases Preliminary 2017 Revenue of $324.5 Million representing a 32% increase over 2016 Fourth Quarter 2017 Preliminary Revenue of $90.9 Million Surpas
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MiMedx Releases Preliminary 2017 Revenue of $324.5 Million representing a 32% increase over 2016 Fourth Quarter 2017 Preliminary Revenue of $90.9 Million Surpasses upper Range of Q4 guidance by Nearly $3 million Mar
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX FORECASTS 2018 REVENUE TO BE IN THE RANGE OF $383 MILLION TO $387 MILLION Marietta, Georgia
PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX FORECASTS 2018 REVENUE TO BE IN THE RANGE OF $383 MILLION TO $387 MILLION Marietta, Georgia, December 13, 2017, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developi
Read more →MDXGMichael Senken Phone: (770) 651-9100 MIMEDX ANNOUNCES RECORD RESULTS FOR THE THIRD QUARTER OF 2017 AND RAISES FULL YEAR REVENUE GUIDANCE MIMEDX OPERATING INCOME GROWS 88% ON 31% REVENUE GROWTH RECO
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MIMEDX ANNOUNCES RECORD RESULTS FOR THE THIRD QUARTER OF 2017 AND RAISES FULL YEAR REVENUE GUIDANCE MIMEDX OPERATING INCOME GROWS 88% ON 31% REVENUE GROWTH RECORD CASH FLOW FROM OPERATIONS OF $18.0 MILLION Mariett
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES THIRD QUARTER REVENUES OF $84.6 MILLION EXCEEDS GUIDANCE BY MORE THAN 5 PERCENT MIMEDX TO HOST CONFERENCE CALL ON WEDNESDAY, OCTOBER 11, 2017 A
PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES THIRD QUARTER REVENUES OF $84.6 MILLION EXCEEDS GUIDANCE BY MORE THAN 5 PERCENT MIMEDX TO HOST CONFERENCE CALL ON WEDNESDAY, OCTOBER 11, 2017 AT 10:30AM EASTERN TIME Marietta, Georgia, October 10, 20
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX COMPLETES DIVESTITURE OF ITS STABILITY BIOLOGICS SUBSIDIARY Marietta, Georgia
PRESS RELEASE CONTACT: PHONE: (770) 651-9100 MIMEDX COMPLETES DIVESTITURE OF ITS STABILITY BIOLOGICS SUBSIDIARY Marietta, Georgia, October 2, 2017, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative
Read more →MDXGPRESS RELEASE CONTACT: MICHAEL SENKEN
PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES ITS EXPECTATIONS FOR THIRD QUARTER REVENUE TO EXCEED $80 MILLION AND SURPASS ITS PREVIOUS REVENUE GUIDANCE Marietta, Georgia, September 5, 2017, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), th
Read more →MDXGMiMedx Logo]] PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX SIGNS DEFINITIVE AGREEMENT TO DIVEST STABILITY BIOLOGICS SUBSIDIARY AS PART OF COMPANY'S STRATEGIC FOCUS ON BIOPHARMA Marietta, Georgia
PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX SIGNS DEFINITIVE AGREEMENT TO DIVEST STABILITY BIOLOGICS SUBSIDIARY AS PART OF COMPANY'S STRATEGIC FOCUS ON BIOPHARMA Marietta, Georgia, August 18, 2017, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), th
Read more →MDXGMichael Senken Phone: (770) 651-9100 MIMEDX ANNOUNCES RECORD RESULTS FOR THE SECOND QUARTER OF 2017 AND RAISES FULL YEAR REVENUE GUIDANCE COMPANY RECORDS 33% REVENUE GROWTH AND A 309% INCREASE IN N
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MIMEDX ANNOUNCES RECORD RESULTS FOR THE SECOND QUARTER OF 2017 AND RAISES FULL YEAR REVENUE GUIDANCE COMPANY RECORDS 33% REVENUE GROWTH AND A 309% INCREASE IN NET INCOME OVER Q2 2016 Marietta, Georgia, July 26, 20
Read more →MDXGMiMedx Announces that its Second Quarter Revenue Exceeds the Guidance Range Q2 2017 Revenue of $76.4 Million is 33% Increase Over Q2 2016 MARIETTA, Ga.
MiMedx Announces that its Second Quarter Revenue Exceeds the Guidance Range Q2 2017 Revenue of $76.4 Million is 33% Increase Over Q2 2016 MARIETTA, Ga., July 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketi
Read more →MDXGMiMedx Agreement With AvKARE Expires As Planned Following Completion Of Contract Wind-Down MARIETTA, Ga.
MiMedx Agreement With AvKARE Expires As Planned Following Completion Of Contract Wind-Down MARIETTA, Ga., July 5, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizi
Read more →MDXGMichael Senken Phone: (770) 651-9100 MIMEDX ANNOUNCES RECORD RESULTS FOR FIRST QUARTER OF 2017 Company records 36% revenue growth, 261% increase in Net Income and 51% increase in Adjusted Net Incom
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MIMEDX ANNOUNCES RECORD RESULTS FOR FIRST QUARTER OF 2017 Company records 36% revenue growth, 261% increase in Net Income and 51% increase in Adjusted Net Income* over Q1 2016 Marietta, Georgia, April 28, 2017, (PR
Read more →MDXGMiMedx Announces First Quarter 2017 Revenue to Exceed High End of Guidance Q1 2017 Revenue of $72.6 Million is 36% Increase Over Q1 2016 MARIETTA, Ga.
MiMedx Announces First Quarter 2017 Revenue to Exceed High End of Guidance Q1 2017 Revenue of $72.6 Million is 36% Increase Over Q1 2016 MARIETTA, Ga., April 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketi
Read more →MDXGMiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors NEWEST MIMEDX BOARD MEMBER IS FORMER COMMISSIONER OF THE U.S. SECURITIES &
MiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors NEWEST MIMEDX BOARD MEMBER IS FORMER COMMISSIONER OF THE U.S. SECURITIES & EXCHANGE COMMISSION MARIETTA, Ga., March 19, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative me
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MiMedx Announces 2016 Record Results Marietta, Georgia
PRESS RELEASE CONTACT: PHONE: (770) 651-9100 MiMedx Announces 2016 Record Results Marietta, Georgia, February 23, 2017, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes
Read more →MDXGMiMedx Fourth Quarter 2016 Revenue in Upper Range of Guidance $246.8 Million Full Year 2016 Revenue is a 32% Increase Over 2015 and $71.6 Million Q4 2016 Revenue is a 38% Increase Over Q4 2015 Marietta, Georgia
MiMedx Fourth Quarter 2016 Revenue in Upper Range of Guidance $246.8 Million Full Year 2016 Revenue is a 32% Increase Over 2015 and $71.6 Million Q4 2016 Revenue is a 38% Increase Over Q4 2015 Marietta, Georgia, January 9, 2017, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MD
Read more →MDXGMichael Senken Phone: (770) 651-9100 MiMedx Announces Third Quarter 2016 Results Company exceeds upper end of guidance with Record Quarterly Revenue of $64.4 Million, a 31% increase over Q3 2015 Ma
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MiMedx Announces Third Quarter 2016 Results Company exceeds upper end of guidance with Record Quarterly Revenue of $64.4 Million, a 31% increase over Q3 2015 Marietta, Georgia, October 27, 2016, (PR Newswire) -- MiM
Read more →MDXGThird Quarter 2016 Revenue Highlights:
MiMedx Third Quarter 2016 Revenue Exceeds Upper End of Guidance $64.4 Million Q3 2016 Revenue is 31% Increase Over Q3 2015 MARIETTA, Ga., Oct. 10, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue a
Read more →MDXGMichael Senken Phone: (770) 651-9100 MiMedx Announces Second Quarter 2016 Results Company exceeds upper end of guidance range and Records Record Quarterly Revenue of $57.3 Million, a 26% increase o
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MiMedx Announces Second Quarter 2016 Results Company exceeds upper end of guidance range and Records Record Quarterly Revenue of $57.3 Million, a 26% increase over Q2 2015 Marietta, Georgia, July 26, 2016, (PR Newswi
Read more →MDXGSecond Quarter 2016 Revenue Highlights:
MiMedx Second Quarter of 2016 Revenue Exceeds Upper End of Guidance Range $57.3 MILLION Q2 2016 REVENUE IS 26% INCREASE OVER Q2 2015 Marietta, Georgia, July 11, 2016, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MiMedx Announces First Quarter 2016 Results Company Records Record QUARTERLY Revenue of $53.4 Million Marietta, Georgia
PRESS RELEASE CONTACT: PHONE: (770) 651-9100 MiMedx Announces First Quarter 2016 Results Company Records Record QUARTERLY Revenue of $53.4 Million Marietta, Georgia, April 25, 2016, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company
Read more →MDXGMiMedx Announces First Quarter of 2016 Revenue Results $53.4 MILLION Q1 2016 REVENUE IS 31% INCREASE OVER Q1 2015 Marietta, Georgia
MiMedx Announces First Quarter of 2016 $53.4 MILLION Q1 2016 REVENUE IS 31% INCREASE OVER Q1 2015 Marietta, Georgia, April 10, 2016, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protecte
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MiMedx Announces 2015 Record Results Company Records Revenue of $187.3 Million, Net Income of $29.4 million and EPS of $0.28 (Basic) and $0.26 (Diluted) Mariett
PRESS RELEASE CONTACT: PHONE: (770) 651-9100 MiMedx Announces 2015 Record Results Company Records Revenue of $187.3 Million, Net Income of $29.4 million and EPS of $0.28 (Basic) and $0.26 (Diluted) Marietta, Georgia, February 23, 2016, (PR Newswire) -- MiMedx Group, Inc. (NA
Read more →MDXGMIMEDX GROUP ALERT – Andrews & Springer LLC Announces Update in the Securities Fraud Lawsuit Against MiMedx Group, Inc. - MDXG
WILMINGTON, Del., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, announced today that a securities fraud class action lawsuit filed on behalf of investors of MiMedx Group, Inc.
Read more →MDXGMiMedx Signs Definitive Agreement to Acquire Stability Biologics Company Issues Revised Guidance and Expects 2016 Revenue in the Range of $260 to $270 Million and Adjusted EPS* in the Range of $0.33 to $0.37 Marietta, Ge
MiMedx Signs Definitive Agreement to Acquire Company Issues Revised Guidance and Expects 2016 Revenue in the Range of $260 to $270 Million and Adjusted EPS* in the Range of $0.33 to $0.37 Marietta, Georgia, January 10, 2016, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG),
Read more →MDXGMiMedx Exceeds Fourth Quarter And Full Year 2015 Revenue Consensus $187.3 million full year 2015 revenue is 58% increase over 2014 and $51.8 million Q4 2015 revenue is 31% increase over Q4 2014 Marietta, Georgia
MiMedx Exceeds Fourth Quarter And Full Year 2015 Revenue Consensus $187.3 million full year 2015 revenue is 58% increase over 2014 and $51.8 million Q4 2015 revenue is 31% increase over Q4 2014 Marietta, Georgia, January 10, 2016, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: M
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES RECORD RESULTS FOR THIRD QUARTER OF 2015 Company Records Revenue of $49 Million, Net Income of $6.6 Million and EPS of $0.06 Marietta, Georgia
PRESS RELEASE CONTACT: PHONE: (770) 651-9100 MIMEDX ANNOUNCES RECORD RESULTS FOR THIRD QUARTER OF 2015 Company Records Revenue of $49 Million, Net Income of $6.6 Million and EPS of $0.06 Marietta, Georgia, October 29, 2015, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG),
Read more →MDXGMichael Senken Phone: (770) 651-9100 MiMedx Third Quarter Record Revenue is $49 million Nine Month revenue increases 72% MiMedx secures $50 million credit facility Marietta, Georgia
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MiMedx Third Quarter Record Revenue is $49 million Nine Month revenue increases 72% MiMedx secures $50 million credit facility Marietta, Georgia, October 12, 2015, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG),
Read more →MDXGMichael Senken Phone: (770) 651-9100
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MIMEDX UPDATES SECOND QUARTER INFORMATION MARIETTA, Georgia, August 6, 2015 (PR Newswire) - MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-prote
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES RECORD RESULTS FOR SECOND QUARTER OF 2015 Company Records Revenue of $45.7 Million and Net Income of $5.4 Million
PRESS RELEASE CONTACT: PHONE: (770) 651-9100 MIMEDX ANNOUNCES RECORD RESULTS FOR SECOND QUARTER OF 2015 Company Records Revenue of $45.7 Million and Net Income of $5.4 Million MARIETTA, Georgia, July 30, 2015 (PR Newswire) - MiMedx Group, Inc. (NASDAQ: MDXG), the leading reg
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MiMedx Announces Record Results for First Quarter of 2015 and Raises Full-year Guidance COMPANY RECORDS REVENUE OF $40.8 MILLION and NET INCOME of $4.1
PRESS RELEASE CONTACT: PHONE: (770) 651-9100 MiMedx Announces Record Results for First Quarter of 2015 and Raises Full-year Guidance COMPANY RECORDS REVENUE OF $40.8 MILLION and NET INCOME of $4.1 MILLION MARIETTA, Georgia, April 27, 2015 (PR Newswire) - MiMedx Group, Inc. (
Read more →MDXGMichael Senken Phone: (770) 651-9100 MIMEDX REPORTS RECORD FIRST QUARTER 2015 REVENUE OF $40.8 MILLION Q1 2015 REVENUE REPRESENTS A 108% INCREASE OVER Q1 2014
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MIMEDX REPORTS RECORD FIRST QUARTER 2015 REVENUE OF $40.8 MILLION Q1 2015 REVENUE REPRESENTS A 108% INCREASE OVER Q1 2014 MARIETTA, Georgia, April 13, 2015 (PR Newswire) - MiMedx Group, Inc. (NASDAQ: MDXG), the leadi
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES 2014 RECORD REVENUE AND FIRST FULL YEAR OPERATING PROFIT Company Records Revenue of $118.2 million, Operating income of $7.1 million and Net In
PRESS RELEASE CONTACT: PHONE: (770) 651-9100 MIMEDX ANNOUNCES 2014 RECORD REVENUE AND FIRST FULL YEAR OPERATING PROFIT Company Records Revenue of $118.2 million, Operating income of $7.1 million and Net Income of $6.2 million MARIETTA, Georgia, February 26, 2015 (PR Newswir
Read more →MDXGMIMEDX GROUP, INC. FRAUD ALERT -- Andrews & Springer LLC Announces That a Securities Fraud Class Action Has Been Filed by a Law Firm Against MiMedx Group, Inc. - MDXG
WILMINGTON, Del., Jan. 26, 2015 (GLOBE NEWSWIRE) -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, announced today that a securities fraud class action lawsuit has been filed on behalf of investors of MiMedx Gr
Read more →MDXGMichael Senken Phone: (770) 651-9100 MIMEDX EXCEEDS FOURTH QUARTER AND FULL YEAR 2014 REVENUE FORECASTS $118.2 MILLION FULL YEAR 2014 REVENUE IS DOUBLE 2013 AND $39.6 MILLION Q4 2014 REVENUE IS 120
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MIMEDX EXCEEDS FOURTH QUARTER AND FULL YEAR 2014 REVENUE FORECASTS $118.2 MILLION FULL YEAR 2014 REVENUE IS DOUBLE 2013 AND $39.6 MILLION Q4 2014 REVENUE IS 120% INCREASE OVER Q4 2013 MARIETTA, Georgia, January 12,
Read more →MDXGMichael Senken Phone: (770) 651-9100 MIMEDX ANNOUNCES $10 MIILLION INCREASE TO STOCK REPURCHASE PROGRAM Marietta, Georgia
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MIMEDX ANNOUNCES $10 MIILLION INCREASE TO STOCK REPURCHASE PROGRAM Marietta, Georgia, January 6, 2015 (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amnio
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX COMMENTS ON RECENT FDA DRAFT GUIDANCE ON MINIMAL MANIPULATION OF HCT/Ps COMPANY REPORTS THAT ITS 4 TH QUARTER AND FULL YEAR 2014 REVENUES WILL EXCEED UPP
PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX COMMENTS ON RECENT FDA DRAFT GUIDANCE ON MINIMAL MANIPULATION OF HCT/Ps COMPANY REPORTS THAT ITS 4TH QUARTER AND FULL YEAR 2014 REVENUES WILL EXCEED UPPER END OF FORECAST Marietta, Georgia, December 30, 2014,
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ACHIEVES RECORD REVENUE AND RECORDS FIRST OPERATING PROFIT Company Records $3.7 million in Operating income on $33.5 million in revenue
PRESS RELEASE CONTACT: PHONE: (770) 651-9100 MIMEDX ACHIEVES RECORD REVENUE AND RECORDS FIRST OPERATING PROFIT Company Records $3.7 million in Operating income on $33.5 million in revenue MARIETTA, Georgia, October 30, 2014 (PR Newswire) - MiMedx Group, Inc. (NASDAQ: MDXG),
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX THIRD QUARTER REVENUE OF $33.5 MILLION EXCEEDS UPPER END OF GUIDANCE REVENUE INCREASES 31% SEQUENTIALLY AND 108% OVER 2013 THIRD QUARTER AND COMPANY RECO
PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX THIRD QUARTER REVENUE OF $33.5 MILLION EXCEEDS UPPER END OF GUIDANCE REVENUE INCREASES 31% SEQUENTIALLY AND 108% OVER 2013 THIRD QUARTER AND COMPANY RECORDS FIRST QUARTERLY OPERATING PROFIT COMPANY PROVIDES PR
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 Correction - MiMedx Group, Inc. In the news release MiMedx Announces Record Second Quarter Results, issued 28-Jul-2014 by MiMedx Group, Inc over PR Newswire, we
CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 Correction - MiMedx Group, Inc. In the news release MiMedx Announces Record Second Quarter Results, issued 28-Jul-2014 by MiMedx Group, Inc over PR Newswire, we are advised by the company that under the "Highlights include section"
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES $10 MILLION STOCK REPURCHASE PROGRAM Marietta, Georgia
PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES $10 MILLION STOCK REPURCHASE PROGRAM Marietta, Georgia, May 12, 2014 (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent-protected regener
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES RECORD QUARTERLY RESULTS Revenue Increases by 69% Over 2013 First Quarter Marietta, Georgia
CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES RECORD QUARTERLY RESULTS Revenue Increases by 69% Over 2013 First Quarter Marietta, Georgia, April 25, 2014, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer o
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX FIRST QUARTER REVENUE EXCEEDED UPPER END OF GUIDANCE COMPANY ANNOUNCES SECOND QUARTER REVENUE GUIDANCE Marietta, Georgia
PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX FIRST QUARTER REVENUE EXCEEDED UPPER END OF GUIDANCE COMPANY ANNOUNCES SECOND QUARTER REVENUE GUIDANCE Marietta, Georgia, April 7, 2014 (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated develo
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES RECORD 2013 RESULTS COMPANY INCREASES SALES FORCE BY 45% SINCE FIRST OF THIS YEAR Marietta, Georgia
PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES RECORD 2013 RESULTS COMPANY INCREASES SALES FORCE BY 45% SINCE FIRST OF THIS YEAR Marietta, Georgia, February 26, 2014 (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, man
Read more →MDXGMichael Senken Phone: (770) 651-9100 MiMedx Prices $34.0 Million Public Offering of Common Stock Marietta, Georgia
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MiMedx Prices $34.0 Million Public Offering of Common Stock Marietta, Georgia, December 11, 2013 (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protect
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX GROUP ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Marietta, Georgia
PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 Marietta, Georgia, December 9, 2013 (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from hum
Read more →MDXGMIMEDX 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against MiMedx Group, Inc. -- MDXG
NEW ORLEANS, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until November 8, 2013 to file lead plaintiff applicat
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES RECORD THIRD QUARTER RESULTS Marietta, Georgia
CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES RECORD THIRD QUARTER RESULTS Marietta, Georgia, October 30, 2013, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials
Read more →MDXGMIMEDX GROUP, INC. DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against MiMedx Group, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of November 8, 2013 -- MDXG
NEW YORK, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased MiMedx Group, Inc. ("MiMedx" or the "Company") (Nas
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX TO EXCEED HIGH END OF THIRD QUARTER GUIDANCE Marietta, Georgia
PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 Marietta, Georgia, October 16, 2013, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from hu
Read more →MDXGMiMedx Group, Inc. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Against MiMedx Group, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of November 8, 2013 -- MDXG
NEW YORK, NY--(Marketwired - Oct 15, 2013) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased MiMedx Group, Inc. ("MiMedx" or the "Company") (NA
Read more →MDXGMIMEDX ENVIRONMENTAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against MiMedx Group, Inc. - MDXG
NEW ORLEANS, LA--(Marketwired - Sep 9, 2013) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 8, 2013 to file lead plaintiff applications in a securities class action l
Read more →MDXGEvent ID: 5129761 Culture: en-US Event Name: Q2 2013 MIMEDX GROUP INC Earnings Conference Call Event Date: 2013-07-31T14:30:00 UTC ****************************************************** Notes: Converted From Text Transcr
Event Name: Q2 2013 MIMEDX GROUP INC Earnings Conference Call Event Date: 2013-07-31T14:30:00 UTC ****************************************************** Converted From Text Transcript Event Name: Q2 2013 MIMEDX GROUP INC Earnings Conference Call Event Date: 2013-07-31T14:30:
Read more →MDXGMICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES RECORD SECOND QUARTER RESULTS Marietta, Georgia
CONTACT: MICHAEL SENKEN PHONE: (770) 651-9100 MIMEDX ANNOUNCES RECORD SECOND QUARTER RESULTS Marietta, Georgia, July 31, 2013, (PR Newswire) -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials a
Read more →MDXGMichael Senken Phone: (770) 651-9100 MARIETTA, Ga.
PRESS RELEASE Contact: Michael Senken Phone: (770) 651-9100 MARIETTA, Ga., July 15, 2013 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic memb
Read more →MDXGMiMedx Group, Inc. [MDXG] to Ring The NASDAQ Stock Market Opening Bell
ADVISORY, July 11, 2013 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. [MDXG], an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane, will visit the NASDAQ MarketSite in Times Squar
Read more →MDXGMichael Senken Phone: (678) 384-6720 MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
PRESS RELEASE Contact: Michael Senken Phone: (678) 384-6720 MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America KENNESAW, Georgia, May 20, 2013 (PR Newswire) - MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of paten
Read more →MDXGMICHAEL SENKEN PHONE: (678) 384-6720 MIMEDX ANNOUNCES RECORD FIRST QUARTER 2013
PRESS RELEASE CONTACT: MICHAEL SENKEN PHONE: (678) 384-6720 MIMEDX ANNOUNCES RECORD FIRST QUARTER 2013 RESULTS KENNESAW, Georgia, May 1, 2013, (PR Newswire) -- MiMedx Group, Inc. (NasdaqCM: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerat
Read more →MDXGMichael Senken Phone: (678) 384-6720 MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market MiMedx Common Stock to begin trading on NASDAQ under the symbol "MDXG" on
PRESS RELEASE Contact: Michael Senken Phone: (678) 384-6720 MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market MiMedx Common Stock to begin trading on NASDAQ under the symbol "MDXG" on April 25, 2013 Kennesaw, Georgia, April 22, 2013 (PR Newswire) - MiMedx Grou
Read more →MDXGMichael Senken Phone: (678) 384-6720 MIMEDX ANNOUNCES 2012
PRESS RELEASE Contact: Michael Senken Phone: (678) 384-6720 MIMEDX ANNOUNCES 2012 RESULTS KENNESAW, Georgia, March 7, 2013 (PR Newswire) MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioi
Read more →MDXGMichael Senken Phone: (678) 384-6720
PRESS RELEASE Contact: Michael Senken Phone: (678) 384-6720 MIMEDX GROUP ANNOUNCES RECORD THIRD QUARTER RESULTS AND RAISES REVENUE ESTIMATES FOR THE YEAR KENNESAW, Georgia, October 29, 2012 (PR Newswire) MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer
Read more →Competitive Position
How MDXG ranks across every disease it competes inCompetitive Position is a premium feature
See how MDXG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial